

Annual report and financial statements

2025



Contents

What it's like living with Parkinson's in 2025	4
Chair and Chief Executive introductions	6
We are Parkinson's UK	10
Strategic report	12
Together, we achieved so much in 2025	12
Delivering on our strategy	14
Fundraising in 2025	18
Getting you new treatments, faster	22
Pushing for excellent health and care	26
Building your community of support	28
Becoming fit for the future	30
How we funded change	32
Our finances in 2025	33
An ethical and effective organisation	38
Setting ourselves up for success: Section 172 statement	45
Principal risks and uncertainties	48
Structure, governance and management	52
Our ethical framework	57
Streamlined energy and carbon reporting	59
Subsidiaries and related parties	63
Statement of trustees' responsibilities	64
Independent auditor's report	66
Financial statements	71
Reference and administrative details	102
Thank you	104



Front cover images:
(Left) Angela and Colin, Parl, World Parkinson's Day 2025
(Top right) Alastair with Parkinson's Nurse, Aberdeen, 2025
(Bottom right) The Brain Bank, Imperial College London, funded by Parkinson's UK and the MS Society

Inside cover image:
Living well with Parkinson's, Salisbury, 2025

What it's like living with Parkinson's in 2025

In 2025, there were more than 166,000 people in the UK living with Parkinson's. We aim to help all of them live well with the condition: getting the most effective treatment and care, and continuing to work and do the things they enjoy as long as possible.

Here's what that looked like for Mo and Debbie in 2025:



Mo's story

Mo was diagnosed with Parkinson's in 2015, when he was 55, and was told about support available from Parkinson's UK shortly afterwards. After joining his local Parkinson's UK group in Uxbridge, Mo eventually became both chair and treasurer. He served in those roles for a year and a half before moving to Margate and joining the local group there. The level of NHS support for Parkinson's in his new home has been disappointing. It took more than two years after the move before he was able to see anyone. And getting support is still a challenge now that he's finally registered with the local health authority.

"Between the consultant and Parkinson's nurse, I've had five appointments cancelled in succession. My last appointment was cancelled just after I sent in the blood pressure data requested for a potential treatment change. The nurse had resigned, and the role remained unfilled for a year."

Mo felt left "in a limbo", and found the lack of a Parkinson's nurse especially frustrating after previously experiencing good access to support. "At least in Uxbridge, my Parkinson's nurse was very responsive. If I had medication issues, I could call her directly, and she'd get back to me within a week or two. I miss that."

As well as helping with local group activities and becoming a committee member, Mo has taken part in a range of research projects to help test treatments and learn more about his Parkinson's. This has included everything from medical trials and sleep studies to physical therapy studies and trying out ballet for Parkinson's.

While waiting for support to find the right treatment, Mo makes sure he stays active. He's aware of how much it helps with his symptoms, even when the condition's frustrating.

“

I used to be very fit – running, swimming, squash, karate – and while I can't do those things now, I do what I can to stay mobile. Despite the aches and pains, I try to stay active – walking, swimming, using light weights in the garden. I just try to keep going with what I can!

”

Debbie's story

Debbie was diagnosed in 2020, aged 48. It took a long time for her to be correctly diagnosed, during which time she had to take long-term medical leave from her job. Eventually, she had to get her young son's help with basic tasks like getting dressed.

After a few years on increasing doses of medication, Debbie's consultant referred her for deep brain stimulation (DBS). Debbie has since been able to gradually reduce her medication and has access to support from a DBS nurse via phone calls and emails.

After she was diagnosed, Debbie had a fantastic Parkinson's nurse. "She was absolutely brilliant – one of those people you could email any time of day or night, and she'd ring you back." Then that nurse moved away and hasn't been replaced.

Debbie has also had to teach health professionals about the condition, and thinks better education would have helped her get a diagnosis faster. "A couple of weeks ago, I spent about 20 minutes explaining all about DBS to my GP, and that was one of the senior partners at the surgery."

Attending her local Parkinson's UK group, which Debbie heard about from her nurse, has been great. "At first, I didn't want to go because I didn't want to see my future. But now I love it."

In 2025, Debbie discovered she could still ride a bike. "I didn't think it would be possible. I'm actually better on a bike than walking right now." And she loves spending time with her young son, whose caring responsibilities are lessened now she has more effective treatment.

“

It's not been a straightforward journey, but there have been improvements. I can eat more, I sleep better, and I feel more like myself. I live in hope. We'll get there in the end.

”



Chair's introduction

It has been an honour to represent this resilient community, first as a Trustee and then as Chair. In line with the maximum terms within our Articles, however, I will be standing down as a Trustee at this year's annual members' meeting.

I have met so many remarkable and committed people since my own diagnosis 12 years ago. People living with this, at times, brutal and relentless condition. People watching their loved ones diminish and who see their real stature nonetheless. People who have selflessly committed their professional or personal lives to care and support.

I would have been delighted to have been able to share news of a cure during this time – whoever created it. This, though, has remained stubbornly “five years away”, as the news about research has seemed to be saying for many years now.

The recent return of humanity into space in Artemis II also served as a reminder that Levodopa, a drug first available before Neil Armstrong made his famous steps (and before I was born), remains the “Gold standard” for treating Parkinson's.

Against these negatives, however, there are increasing improvements in the ways we can manage the condition. Parkinson's UK now supports over 2,000 programmes in exercise, mutual support, voice, dance, the arts and wellbeing annually across the UK, and has major partnerships with Sport Parkinson's and Everyone Active.

Technology is also helping inform our community on what can work for them. Our Tech Guide, which was part-funded by the Michael J Fox Foundation, was visited by over 40,000 people in 2025.

That's just one example. Information, expertise and experience are increasingly being combined to personalise our service to our community's needs, and to measure how they feel about the outcomes we've delivered, and the actions we've taken.

“

In 2025, the team simplified the requirements of volunteering, improved our dedicated service for the newly diagnosed, and increased access to expertise for more people. With your help, we funded and protected roles for more Parkinson's nurses, neurologists and specialist physiotherapists.

”



We have increased services for those of working age and recognised the different needs of different parts of our community. Working in partnership with the Movers and Shakers and other influencers, we are bringing to life the gaps, weaknesses and successes in NHS services. We are increasingly recognised and valued by government for our relevance and for providing access to exceptional expertise.

But Parkinson's, in my view, is about attitude almost as much as it is about facts. In supporting each other, we don't deny this condition: we take control of it. In enjoying life after Parkinson's, we don't ignore its impact: we refuse to let it define us. There are days when I wake up without confidence or belief. The belief of those around me helps me focus on what I can do – and so often, I've seen those days turn into great memories.

I'd like to thank all the volunteers across the charity including our brilliant President, Jane Asher, who is stepping down this year after nearly 20 years. Thank you also to Caroline, and everyone who has, in whatever way, brought care, control and challenge to this community.

This brings me back to research. Collaboration is helping us accelerate trials, and it's clear that working together will help us find the cause of this condition quicker. I see more and more optimism in the eyes of the brilliant scientists around us. Artificial intelligence can accelerate our understanding. This can drive solutions from the unique information sources we have, such as the Brain Bank.

When President Kennedy visited Cape Canaveral before that historic mission, he is said to have asked a cleaner what his job was. His response? “To get us to the moon”.

“

If we act together, with that same purpose, drive and urgency, then we will learn what causes this condition. We will deliver a cure. And we will reduce the pain that Parkinson's causes in all our lives.

”

I'm delighted that Kris Murrin CBE has joined Parkinson's UK and will become Chair when I stand down. I'm confident that Kris will continue to drive the charity's work forward, with the needs of the community at the heart, always.

Live Life, Love Life, Stop Parkinson's!

Gary Shaughnessy CBE
Chair of Board of Trustees

Chief Executive's introduction

It is with immense pride that I reflect on Parkinson's UK's achievements in 2025. Our work was driven by learnings from our landmark study of the prevalence of Parkinson's. Parkinson's is on the rise in the UK. People with Parkinson's are impacted every day by a diagnosis and NHS workforce crisis, with around 21,000 people still waiting for a diagnosis and the professional support that will follow. The study's findings have fuelled our determination to drive significant impact across our four strategic ambitions in the remaining year of our strategy.

Hope for our community remains rooted in research, which is the cornerstone of our mission to transform lives. Our investment in research funds work to understand the causes of Parkinson's, alongside a drug discovery arm with partners around the world to research innovative drugs with the potential to slow or stop progression of the condition and, perhaps one day, prevent Parkinson's entirely.

In 2025, we have seen major research breakthroughs and invested a further £1.6 million into our research programme, which brings our total current research commitment to over £40.8 million. Key progress on potential new treatments included the start of the Phase 3 ambroxol trial and the success of NRG Therapeutics (to which we provided critical initial funding in 2019 and in 2022) in securing £50 million for further clinical trials. Our trailblazing £10 million partnership with the UK Dementia Research Institute secured a new dedicated Parkinson's Research Centre in Edinburgh.

“

To improve care for people with Parkinson's, we focused intensely on tackling the specialist workforce crisis in the NHS. By the end of 2025 our Nurse Appeal had raised over £6.7 million, helping to fund 33 new Parkinson's nurses and allied health professionals in the NHS and so contributing to a 25% reduction in the nurse shortage. Powerful local campaigns secured new NHS investment, helping more people with Parkinson's get the specialist care they need to live well with the condition.

”

We also achieved impressive growth in our community support, with significant increases in the impact of our helpline and local advisers. Our resources for those newly-diagnosed with Parkinson's – including our recently launched 'No Diagnosis Without Support' project – are reaching more people than ever.

This impact was possible thanks to record fundraised income in 2025, demonstrating the commitment of our supporter community. We benefitted from a significant increase in our individual financial supporters and the continued success of the Nurse Appeal.

The Board and Executive Leadership team work hard to ensure that we're a high-performing charity, so we can continue to deliver maximum benefit for people with Parkinson's. In 2025, we implemented more robust performance and impact reporting, so we can better demonstrate the difference our work makes. And we simplified the framework for our volunteer-led local groups, so that volunteering for us remains rewarding and enriching.

While proud of our achievements, challenges remain, such as ensuring enough participants for research trials like the ongoing ondansetron study. We recognise the urgency of delivering more for the Parkinson's community, and our focuses for 2026 include expanding support for those with more advanced Parkinson's and for carers.

“

It remains a privilege to work with and for this community. I'm excited about what we can achieve together, and I look forward to sharing this year our ambitious strategy for 2027 and beyond.

”

C. J. Russell

Caroline Russell
Chief Executive





Lucinda and Katherine, Parkinson's UK volunteers, PIP open letter hand-in, June 2025

We are Parkinson's UK

We're the charity that's here to support every Parkinson's journey, every step of the way.

It all started with Mali Jenkins. Mali's sister, Sarah, had Parkinson's. When Mali looked for information about the condition, she didn't find anything helpful. But she didn't give up. Mali reached out to others living with Parkinson's to share experiences. And in 1969 she founded Parkinson's UK and our journey began.

Over 50 years later, we haven't stopped. Today, we're the UK's leading charity working with and on behalf of the estimated 166,000 people with Parkinson's in the UK, and the over

1 million people who love and support them. As the only charity in the UK that takes action on every aspect of living with Parkinson's, we're here for every Parkinson's journey.

We're a united community of people living with Parkinson's – and families, volunteers, campaigners, fundraisers, scientists and health and care workers – across the UK. **Together, we share one mission: to make life with Parkinson's better, today and in the future.**

Our areas of work

We believe that together we'll find a cure. But that's not all we're working for. We're taking action in four ways:



Getting you new treatments, faster.

We support research powered by people with Parkinson's, every step of the way. We're searching for the causes of Parkinson's and for a cure. And we're developing better treatments, right now.



Pushing for excellent health and care.

We push for great care everywhere for people with Parkinson's, by funding new specialist nurses, offering sector-leading education for health and care professionals, and campaigning for better NHS services.



Building your community of support.

We make sure people with Parkinson's, and those who love and care for them, have access to the support they need. So they can live well with the condition at every stage of their Parkinson's journey.



Becoming fit for the future.

We empower every one of our supporters, volunteers, members and staff to drive change, by equipping them with the tools they need to have the biggest impact for people with Parkinson's. And we raise the money we need to continue funding our ambitious strategy.

Our members

Our members are a strong and supportive community of over 41,000 people. Becoming a member gives you community connections, information and support, and opportunities to be heard and help make a difference to our work. And by growing our membership and bringing them together, we have a stronger voice with UK governments, the NHS and wider society. That makes us better placed to take action on behalf of people with Parkinson's, to improve funding and services, and grow understanding of Parkinson's. Parkinson's UK membership is free of charge, and the more people who join, the bigger the impact we can make.



Membership of Parkinson's UK is important to me because I want to be able to spread awareness. It would be very easy to feel isolated with such an unpredictable condition, and being a member of Parkinson's UK makes me feel part of a community.

Parkinson's UK member



To become a member – free of charge – please go to our website or contact our Supporter Care team (details on back page).

Together, we achieved so much in 2025



Anita, living with Parkinson's, research volunteer

33

Parkinson's nurses and allied health professionals funded in the NHS.

At Bradford Teaching Hospitals NHS Foundation Trust, the Neuro Rehabilitation team has seen the positive impact of the funding we have provided through our pump priming scheme. New occupational therapist and physiotherapist posts, seed funded by us, reduced waiting times for therapy assessments by two-thirds. This improvement to the service reduces the risk of rapid deterioration, secondary complications and hospital admission: saving money and improving quality of life for people with Parkinson's.

£6.9m

given in research grants.

8

promising new drug treatments in clinical trials.



95%

of researchers said we had a positive impact on recruitment to their project.

84

research projects we helped involve and include the Parkinson's community.




Tracey and Elisabete, Parkinson's nurses



MP Alex Barros-Curtis and Colin, Parl, World Parkinson's Day 2025

39%

increase in MPs rating Parkinson's UK as effective since November 2024.



15,517

people supported by our helpline. Together, there were 20,214 calls with these people.

14,608

people helped by our Parkinson's local advisers.

96% feel better able to make changes.

97% feel more in control.

95% experienced an improvement to their wellbeing.

100% feel better informed of what support and services are on offer.

2,610

average monthly visitors to our Tech Guide, which shares information and honest reviews about devices, apps, and solutions to help people with Parkinson's make informed decisions.

467

groups, cafes and virtual networks across every region of the UK, connecting the Parkinson's community together, including the LGBTQIA+ network, Young Onset Parkinson's group, and Black, Asian, Arab and Mixed Heritage Support Group.



£45.4m

raised to fund our strategy.



Par-Con, Birmingham, 2025

Delivering on our strategy



Getting you new treatments, faster

What we said we'd do in 2025

- Continue our ambitious research programme, with an investment of over £40m.
- Launch a new £10m research centre in partnership with the UK Dementia Research Institute.
- Engage more people with research, particularly those from underrepresented ethnic communities.
- Expand our Tech Guide service to help communicate how technology can help manage Parkinson's.

We report back on pages 22 to 25.

Our key goals for 2026

- Accelerate recruitment to our pivotal UK-wide trial of ondansetron as a potential new treatment for hallucinations with Parkinson's.
- Increase the number and accelerate the progress of promising treatments for Parkinson's through our pioneering drug development initiative.
- Complete recruitment of the expert team leading the new UK Dementia Research Institute Centre and establish it as a unifying force for Parkinson's research in the UK.
- Encourage more people to sign up to take part in Parkinson's research, including in particular the groundbreaking EJS ACT-PD trial (Edmond J Safra Accelerating Clinical Trials in Parkinson's).





Pushing for excellent health and care

What we said we'd do in 2025

- Continue seed funding of NHS Parkinson's nurse and allied health professional posts.
- Provide fellowships to attract new doctors to Parkinson's practice.
- Publicly launch a new fundraising appeal around Parkinson's nursing and specialist healthcare.

We report back on pages 26 to 27.

Our key goals for 2026

- Seed fund at least four new nurse or allied health professional NHS posts in areas with a desperate need for improved access to NHS care.
- Push for newly diagnosed people with Parkinson's to be supported from day one.
- Campaign to attract more nurses to specialise in Parkinson's, tackling the major issue that half of Parkinson's nurses working in 2022 are set to retire by 2032.
- Use data from our recent audit of almost 700 NHS services to fight for improvements to local services.
- Push for more access to existing and new treatments.
- Campaign for much-needed improvements to benefits, so people with Parkinson's can afford to live well.
- Fight for improvements to the Blue Badge scheme, to end the postcode lottery.
- Educate thousands more health and care professionals so they can better care for people with Parkinson's.





Building your community of support

What we said we'd do in 2025

- Grow our community services to reach more people with Parkinson's than ever before, from people who are newly diagnosed to those needing advanced care and support.
- Add 300 new local activity opportunities, and fund at least 60 new projects, to help people with Parkinson's get active and stay active.

We report back on pages 28 to 29.

Our key goals for 2026

- Increase the reach of our expert adviser services through our helpline and colleagues across the UK.
- Build upon our rapidly growing newly diagnosed support by launching our "No Diagnosis Without Support" project.
- Expand our support for people who are currently inactive to take their first steps towards becoming physically active.
- Address loneliness and isolation by expanding our peer support offer for carers, people with more advanced Parkinson's, and people who need or want a different offer from that provided by our existing groups.
- Find new ways to make volunteering easier for the thousands of dedicated volunteers who support the community.



Together We Get Active campaign with people living with Parkinson's, 2024



Becoming fit for the future

What we said we'd do in 2025

- Use new technology and smarter ways of working to make Parkinson's UK as efficient as possible.
- Use the insights from our "prevalence and incidence" study to push for better services and plan our activities.
- Make it easier to find help on our website.
- Improve the tools used by our community-based colleagues.

We report back on page 30.

Our key goals for 2026

- To make it easier and more engaging and enriching to work and volunteer for us, we will upgrade our volunteer management system and our recruitment and finance tools.
- To enhance the experience of our donors and members and to improve our efficiency and effectiveness, we will implement a new customer relationship management system.
- To enable a future where AI improves the lives of people with and affected by Parkinson's, we will develop a strategy to responsibly leverage AI to maximise our impact.



Paul, living with Parkinson's, research volunteer

Fundraising in 2025

In 2025, the Group's total income was £51.6m. This is a growth of 6% compared to £48.6m in 2024.

Fundraised income this year was the highest in the charity's history, reflecting sustained growth and the strength of our supporter community. This achievement is particularly significant given the challenging fundraising environment across the sector, with many organisations experiencing increased pressure on voluntary income.

Our performance demonstrates the effectiveness of our fundraising strategy and the commitment of our donors, partners and volunteers. These results place us firmly on the trajectory projected when we launched our current fundraising strategy, reinforcing our confidence that we are on track to achieve our planned growth through to 2028.



The Brain Bank, Imperial College London – funded by Parkinson's UK and the MS Society

Advancing new treatments through global collaboration

Our longstanding collaboration with the Parkinson's Foundation continued to play a significant role in advancing the vital work of Parkinson's Research Ventures (part of Parkinson's UK, and previously known as The Parkinson's Virtual Biotech). Please see page 23. This partnership demonstrates the value of global collaboration in tackling complex conditions like Parkinson's.

2025 achievements included the success of NRG Therapeutics, which secured £50m of additional Series B investment to move their drug into clinical trials. And significant progress was made in other trials testing potential new treatments, such as the Herantis Pharma growth factor (HER-096) and the repurposed cough medicine ambroxol.

Coming together for the Nurse Appeal

The Parkinson's UK Nurse Appeal continued to gain momentum, bringing together a group of strategic donors and partners committed to improving care for people living with Parkinson's. Support from cornerstone and lead funders has been instrumental in helping us drive the appeal forward and build the long term investment needed to expand access to specialist Parkinson's nurses and other healthcare professionals across the UK.

Among these key partners are the Frank Brake Charitable Trust, the Garfield Weston Foundation and the National Garden Scheme. Their leadership and generosity have helped establish a strong foundation for the appeal, while also encouraging wider philanthropic support from philanthropists, trusts and

foundations who share our ambition to strengthen Parkinson's care, now and into the future. The National Garden Scheme, our partner since 2012, continued its longstanding commitment in 2025 with a donation of £450,000 and a pledge of ongoing support for this critically important area of our work.

Together with thousands of other supporters, these strategic partnerships helped generate more than £3 million for our Nurse Appeal during the year. This will fund new nurse and allied health professional roles, enable training and education for health and care professionals, and bring us closer to our goal: that everyone living with Parkinson's has access to the specialist care they need to live well with the condition. The Nurse Appeal entered 2026 with £6.7 million in donations received or pledged.



Tracey and Elisabete, Parkinson's nurses

A Night at the Roundhouse

In November 2025, supporters gathered at the Camden Roundhouse for *Parkinson's UK Presents: A Night at the Roundhouse*, our flagship gala in support of the Nurse Appeal. The evening brought together philanthropists, corporate partners and long-standing supporters from our community with a shared commitment to expanding access to specialist Parkinson's nurses.

The event was led by our Flagship Event Committee, chaired by Andrew Greasley and supported by Guy Addison, John Altman, Lisa Anderson, Mark de Lisser, Charlotte Edwards, Paul Gordon, Felicity Percy, Steve Sidwell, Matt Voss, Jodie Wilson, Simon Woodlock and Anthony Yates. Through their efforts, including securing tables and sponsorship, sourcing auction prizes and helping to secure talent, the committee helped deliver a memorable evening.

Hosted by Brian Conley, the night included performances from Alexandra Burke, Lo Lauren, Adam O'Connor, Samantha Spiro, and The George Michael Singers, with a heartfelt speech from Clare Lindley about her journey from diagnosis to becoming a Parkinson's nurse. The event raised £382,000 for the

Nurse Appeal: funding that will support three Parkinson's nurses for two years, helping nearly 1,000 more people access specialist care and support.



Donations

We saw lower year-on-year income from membership, raffles and appeals, and a small drop in unsolicited general donations. However, the number of online donations increased to 17,535, up 8% from last year (16,183 in 2024) and raising £2m. This is an increase of 18% from last year (£1.7m in 2024). In addition, income from committed giving rose 1.6% to £1.31m (£1.29m in 2024),

and payroll giving also increased by 23% to £188,000 (nearly £153,000 in 2024).

It was also a strong year for legacy donations. We were notified of 642 new legacy gifts throughout the year, and our total income, including legacy gifts to local groups, reached £25.4m. We're tremendously grateful to everyone who remembers us in their wills, and for the work they enable us to do in support of people with Parkinson's.

Events and community fundraising

We're delighted that support for our events and community fundraising has continued to go from strength to strength. Our 12,326 wonderful and committed participants (up 7% from 2024) raised a total of £7.86m (up 13% from £6.97m). 2025 was our best year to date for fundraising for both the London Marathon and the Great North Run. We saw growth in participation and money raised across all our events, including the Manchester Half and Full Marathons, the Hackney Half Marathon, the Cardiff Half Marathon, the Kiltwalks, and in-celebration events.

Philanthropy and partnerships

Income from philanthropists, trusts, statutory and corporate partners increased by 5% from 2024. This growth reflects the continued development of our relationships with high value supporters and partners across philanthropy, trusts and the corporate sector. Their support is vital to advancing our mission to help everyone with Parkinson's live well.

In 2025, partners supported a broad portfolio of work across the charity, from pioneering research programmes advancing understanding of the condition and making new drug discoveries, to services and community support for people living with Parkinson's and those who love and care for them. Our Nurse Appeal (see page 19) also provided a clear focus for partnership during the year.

Supporter numbers



119,685

individual financial supporters
(compared to 104,631 in 2024 – a 14.4% increase).

81,200

new supporters (against a target of 72,000).

38,500

existing or retained supporters
(against a target of 38,000).

Events and community fundraising

12,326

combined total participants, an increase of 7% (compared to 11,519 participants in 2024).

£7.86m

combined total income raised.



Getting you new treatments, faster

We're at the forefront of work around the world aimed at understanding the causes of Parkinson's and developing new treatments – and ultimately finding a cure – for the condition. Current medications help manage symptoms, but cannot prevent or reverse the progression of the condition.

As the leading UK charity for Parkinson's research, we have a multi-million pound funding programme, decades of experience, strong international networks, and a fantastic community of people with Parkinson's powering our research.

Investigating the causes of Parkinson's

Since the charity was founded in 1969, we've funded breakthrough science to understand the complex causes of Parkinson's, why and how brain cells are lost, and how the condition progresses. This knowledge is the foundation on which exciting new treatments with the potential to slow or stop the progression of Parkinson's have been developed.

However, despite huge leaps forwards in our understanding of the causes of Parkinson's, there are still big gaps in our knowledge that could hold the answer to a future cure. That's why we continue to invest in research to push the boundaries of our knowledge and understanding.

In 2025, we announced our trailblazing £10 million partnership with the UK Dementia Research Institute to create a new dedicated Parkinson's Research Centre, led by Professor Miratul Muqit at the University of Edinburgh. The new centre will bring together leading researchers dedicated to further

understanding the causes of Parkinson's. Identifying the mechanisms by which Parkinson's develops and progresses will provide new approaches to diagnose and monitor the condition, and ultimately to find new treatments to prevent, stop, and cure Parkinson's.



It is an absolute honour to lead the new UK Dementia Research Institute Parkinson's Research Centre in partnership with Parkinson's UK. As a practising neurologist I am acutely aware of the lack of disease-modifying therapies for people with Parkinson's.

Prof Miratul Muqit



Accelerating new treatments for Parkinson's

In 2025, we saw significant progress across the Parkinson's Research Ventures programme, our global drug discovery and development programme (formerly the Parkinson's UK Virtual Biotech programme). Parkinson's Research Ventures identifies projects with the potential to transform life for people with Parkinson's, and collaborates with partners, researchers, and the Parkinson's community to develop and test them.

Parkinson's Research Ventures' highlights in 2025 include:

- the start of ASPro-PD, the Phase 3 trial of ambroxol led by University College London. This clinical trial, which we're co-funding, began in April, and is looking

at the potential of a cough medicine called ambroxol to treat Parkinson's

- the start of our trial into a drug called SNT-4728, in collaboration with Australian drug discovery company Syntara Therapeutics. The trial, which began in May, could lead to understanding of whether the drug could be used to prevent or slow the development of Parkinson's
- promising results from phase I trials of HER-096, a potential new drug treatment developed by Herantis Pharma to slow or stop Parkinson's. Results of the trial, which we funded in partnership with the Parkinson's Foundation and the Michael J. Fox Foundation, came out in October.

NRG Therapeutics

Early investment from Parkinson's Research Ventures in 2019 and 2022 was key to the success of drug development company NRG Therapeutics in 2025 to attract other funding of £50m. This funding will enable it to advance its drug, NRG5051, into clinical trials. NRG acknowledged the crucial role of Parkinson's Research Ventures' endorsement in helping it to secure multiple grant awards and investment from mainstream healthcare investors.

NRG5051 is a tablet designed to help repair damage to the mitochondria in people with Parkinson's, and motor neurone disease. This means it has the potential to slow or stop the progression of Parkinson's. The upcoming clinical trials will focus on assessing the drug's safety and making sure it enters the brain. As an active founding investor, we

hold an observer seat on the board of NRG Therapeutics and will continue to support the company's progress.

Collaboration with the Parkinson's Foundation

The Parkinson's Foundation, which is based in the US and works to improve care and advance research towards a cure, contributed US\$750,000 during the year as part of our multi-year, multi-million dollar partnership. This reflects a shared commitment to accelerating the development of new treatments that improve life for people living with Parkinson's.

Working together continues to strengthen the international reach of the programme, and allows us to invest in some of the most promising opportunities in Parkinson's drug development.

Pioneering new ways to address symptoms

There are over 40 symptoms of Parkinson's, from tremor and stiffness to problems with sleep and mental health. But current treatments are limited.

We're funding a wide range of pioneering projects that could deliver new ways to manage debilitating symptoms.

In 2025, these included:

- a study led by researchers at the University of Nottingham to test whether a wrist-worn device that delivers electrical stimulation could help to reduce tremor for people with Parkinson's
- a study led by researchers at the University of Cambridge investigating whether ginger supplements can improve inflammation and gut symptoms in people with Parkinson's
- a project led by researchers at the University of Exeter to develop videos to help people with Parkinson's overcome freezing.

Collaborating globally for the biggest impact

As many of our research investments reflect, we're proud to be conveners of international cooperation in medical research, supporting collaboration between organisations and researchers in multiple countries for a truly global perspective.

The Critical Path for Parkinson's is a global public-private initiative to improve clinical trials for Parkinson's co-founded by Parkinson's UK and the Critical Path Institute in 2015. It celebrated its 10th anniversary in 2025 and continues to go from strength to strength.

This visionary programme now brings together 17 industry partners, including global pharmaceutical and biotech companies, with nine non-profit organisations. In 2025, the programme announced a new landmark initiative, Global Evidence in Medicine for Parkinson's Disease (GEM-PD), dedicated to advancing knowledge on how Parkinson's uniquely impacts women around the world.

Bringing research to everyone with Parkinson's

Most Parkinson's research needs people with the condition to take part. And we know that being involved in research has many benefits for people with the condition and their loved ones.

We're working hard to help everyone with Parkinson's get involved in research if they would like to, so they can be a part of accelerating the journey to better treatments and a cure.

In 2025, our participation and involvement outreach included:

- 11,000 members of our Research Support Network, who receive regular research news and opportunities to get involved
- over 8,000 users of our Take Part Hub, who get involved in research studies
- 50 projects supported with recruitment
- 551 volunteers, who work with our Research team to steer, shape and deliver our research activities
- research events in all four nations of the UK, to give people access to the latest information and to encourage them to get involved.

We know that some members of the Parkinson's community, particularly those from Black, Asian and other minority ethnic backgrounds, are less likely to have the opportunity to be involved in research. We established our pioneering Race Equality in Research programme in 2021, in partnership with people with Parkinson's from underrepresented backgrounds, to help us make research more accessible to the entire Parkinson's community. Since the start of the initiative in 2021, the percentage of people with or connected to Parkinson's from minority ethnic backgrounds joining our Research Support Network has more than doubled.

Tech Guide

Our Tech Guide helps people with Parkinson's learn more about the many assistive devices and apps available to them, supporting people to make the right choices for them. Every review is shaped by members of the Parkinson's community and examined before publication by our steering group: an amazing group of people with Parkinson's and family members. Since launching at the end of 2024, the Tech Guide grew throughout 2025 to include 58 products (from 38) and 17 completed panel reviews (from 4).

In 2025, the Tech Guide won a Made With Patients award from Patient Focused Medicines Development. This is a global award scheme that recognises excellent patient involvement, and we're proud to be recognised in this way.

Key figures

54

research projects worth over £40m.

8

promising new drug treatments in clinical trials.



1,399

new members of our Research Support Network.

50+

research studies supported with finding participants.

80+

research projects benefited from the voice of lived experience.

1,000+

people reached by research events held across all four nations.



40,000

people visited our online Tech Guide.

Pushing for excellent health and care

Key figures

26%

reduction in NHS Parkinson's nurse shortage across the UK, from 128 to 95.

91%

success rate defending services under threat.

12

new online education courses launched.

Closing the nursing gap

People with Parkinson's are waiting too long to access care due to longstanding shortages of specialist health professionals. We estimate that one in five people with Parkinson's across the UK have little or no access to a Parkinson's nurse. This delays treatment, worsens outcomes, and has a wider impact on the UK economy.

During 2025, we provided funding for 15 Parkinson's nurses in the NHS through our pump priming scheme and agreed to fund four newly-created posts in London, Derby, East Lancashire and Tayside. These new posts will be filled in 2026.

Thanks to the relentless work of local campaign volunteers, we've also prevented the removal of nurse posts and pushed for investment in local NHS services. We secured the retention of a second Parkinson's nurse at Southend Hospital and agreement to create specialist nurse posts in Chelmsford, Basildon, and Leicester.

We supported the expansion of allied health professional posts in the NHS too. In 2025, we provided funding for 18 allied health professionals in the NHS through our pump priming scheme, and agreed to fund one newly-created speech and language therapist post in Harrogate. This new post was filled in January 2026.

The NHS diagnosis and workforce crisis

Our work to create new posts in the NHS and fight to save existing ones is happening within a crisis in NHS services for people with Parkinson's. Our highly-regarded study of the prevalence of Parkinson's in the UK gave an alarming insight into diagnosis waiting times. Up to 21,000 people are currently living with Parkinson's without a diagnosis, and therefore without support. Meanwhile, people with Parkinson's report long waits for ongoing care or difficulty in accessing vital specialists, such as physiotherapists and speech and language therapists.

In 2025, we made the case for investment in Parkinson's NHS services in our response to the government's consultation on the 10 Year



Gary, living with Parkinson's, with healthcare professional, December 2025

Health Plan for the NHS in England. In 2026, we will urge ministers to tackle the workforce crisis through the upcoming 10 Year NHS Workforce plan.

Growing our influence to push for change

2025 was a great year for building awareness of Parkinson's in parliaments across the UK. Our 2025 highlights include:

- successfully campaigning to stop the UK Government from restricting eligibility for the disability benefit, Personal Independence Payment (PIP)
- briefing Westminster MPs to talk knowledgeably about Parkinson's during three dedicated debates, voicing strong cross-party support for our services and campaigns
- hosting a parliamentary reception in Westminster to mark the 10-year anniversary of the Parkinson's UK Excellence Network, attended by around 60 MPs and peers
- an event at the Senedd in Wales, where we showcased partnership work with Choirs for Good and spoke directly with 20 Members of the Senedd about Parkinson's-related issues
- a reception in Scotland attended by 28 MSPs and the Minister for Public Health, Jenni Minto MSP, where members of the Parkinson's community highlighted the benefits of physical and creative activity.

“

It has been so encouraging that so many MPs are standing up and being our voice in parliament. I am proud to be a volunteer with Parkinson's UK, and their help and support makes my campaigning role so much easier.

Viv, campaigner

”

Our efforts are paying off, with members of parliaments across the UK becoming more aware about Parkinson's and prepared to take action. In a survey of Westminster MPs, 64% said Parkinson's UK was effective. We won't stop advocating for better NHS care for people with Parkinson's.

Education excellence

Our free online courses for health and care professionals offer a range of learning opportunities for specialists and non-specialists alike. Our new courses in 2025 include: Parkinson's-related dementia; technology; and enabling people with Parkinson's to take part in research.

Following the launch of our Foundation Programme, completion rates for our online courses increased from 30% to 80% during the year, showing the quality and value of the programme.

Parkinson's golf group, Stevenage, 2025

Building your community of support

During 2025, we built on our foundations to grow our reach across the Parkinson's community. We set ourselves ambitious targets, which we've met, and in many cases exceeded. Our feedback from the community tells us that we're providing high-quality support and making a positive difference in the lives of people with Parkinson's and those who love and care for them.

Adviser services

- Our helpline teams and local advisers supported more people in 2025: 25,610 people across the country, a 9% increase from 2024.
- The helpline answered 20,214 calls (15% more than 2024).
- Local advisers supported their clients in 112,474 interactions.

“

[The adviser] has been brilliant. I felt heard and understood. Plus we were able to change things for the better. Communication was excellent and I felt supported.

”

“

The [adviser] I spoke to was extraordinarily helpful, reassuring and patient – I couldn't have asked for anything better.”

“Just speaking to [an adviser] allowed me to see things more clearly. In a nutshell, [the advisers] listened (despite the tears!), were compassionate and totally professional. I was ready to get up and continue.”

“Absolutely fantastic service, I don't know what I would do without Parkinson's UK.”

”

Newly diagnosed

We've improved and expanded our resources for people newly diagnosed with Parkinson's and their loved ones.

- 4,271 people engaged with our newly diagnosed resources in 2025: a growth of 348%.
- Parkinson's Connect, our pioneering programme to allow health professionals to refer people to us at the point of diagnosis, rolled out at 15 new sites across the UK (making a total of 22). As a result, 463 newly diagnosed people were referred to us in 2025 for support from day one.

Online videos

One of our focuses in 2025 was to create accessible video content to help us reach a wider community. Our online videos break down myths and taboos around the condition and are available in English and six South Asian languages (Hindi, Urdu, Punjabi, Gujarati, Bengali and Tamil). In 2025 the videos had 7,000 views from eight different countries.

People with more advanced Parkinson's

Over 2025, we made strong progress in expanding support for carers and people with young onset Parkinson's (with 39 groups for carers and 70 groups for people with young onset Parkinson's now running online or face to face). However we were not able to match this progress for people with more advanced Parkinson's. Understanding how we can best meet their needs, and continuing to improve support for carers and those with young onset Parkinson's, will be a focus for 2026.

Key figures

25,610

people supported by our local advisers and the helpline.

77

new physical activity projects funded across the UK.

4.7 out of 5

average satisfaction score from helpline callers and people supported by local advisers.


The difference the local adviser service makes:

100% feel better informed of what support and services are on offer

99% feel confident to access support

99% feel more understood

98% feel better connected



Becoming fit for the future

With technology constantly changing the ways people with Parkinson's can access information and tools to help them live better with the condition, we work hard to make sure our staff and volunteers, and the Parkinson's community, are getting the biggest impact possible.

Parkinson's UK website improvements

We heard feedback from the Parkinson's community that they value our informative and reassuring online health information, but sometimes struggled to find what they were looking for on our website. At the end of the year, we rolled out improvements to our website designed to make information, support and activities easier to find. These included:

- a new main menu that's easier to quickly scan and understand as well as more accessible, especially for people with motor challenges
- a new Community section to make our groups, online forum and Par-Con more prominent
- more relatable language like "I'm a researcher" or "I care for someone with Parkinson's" to help people identify the most relevant site sections for them.

Other tech improvements

We made improvements to our Shared Information System, used by our Community team to record their interactions with members of the Parkinson's community. This has helped us develop insights into what really matters for people with Parkinson's, and to consider our

regional presence relative to the estimated number of people with Parkinson's. We developed a technology and data roadmap to plan our modernisation path, with an initial focus on launching a new customer relationship management system. This is due to go live by January 2027.

Google makes its Gemini Professional tool available to non-profits at no extra cost. We have rolled out this new suite of productivity tools and provided guidance on appropriate use by staff. This gives us more time to focus on things that make a difference for people with Parkinson's without compromising on our high standards for accuracy and reliability.

Key figures

1.5 million
visitors to our website in 2025.

82/100


accessibility score for our website. Since the launch of our website improvements our increased accessibility score has taken us to 25th place among UK charities.



Dr Julie Jones showing Dr Louise Wood how to use VR goggles

How we funded change


Income £51.6m



- 49% Legacies
- 43% Donations and membership
- 3% Investments and other charitable income
- 5% Other trading activities

“Thanks to the generosity of our incredible supporters, 2025 was a record year for fundraised income.”

Expenditure £52.7m



- 22% Raising funds
- 18% Getting you new treatments, faster
- 17% Pushing for excellent health and care
- 32% Building your community of support
- 11% Becoming fit for the future

Our finances in 2025

Our consolidated financial statements for the year are shown on pages 71 to 101. A summary of the financial results for the year is set out below.

In 2025, our income from legacies, donations, events, grants and other fundraising activities grew by £3.1m. Our income from donations and membership grew by 8.4% to £22m (compared to £20.3m in 2024), driven by an increase in online donations.

Once more, this highlights the resilience of our fundraising and cause for optimism in 2026.

We’re grateful for the support we’ve received from thousands of supporters, volunteers and members who contributed to a fantastic year.



Income streams	2025	2024
Total fundraising income (legacies, donations, grants and other fundraising activities)	£50.4m	£47.3m
Legacies	£25.5m	£24m
Donations and membership	£22m	£20.3m
Grants	£0.2m	£0.4m
Other fundraising activities, including trading	£2.7m	£2.6m
Investments and other sources	£1.2m	£1.3m
Total income	£51.6m	£48.6m
<i>Income generated by local groups (included in income streams above)</i>	£4m	£4m
<i>Legacy pipeline at 31 December (legacies notified to the charity but not recorded as income in the accounts)</i>	£2.2m	£3.5m

Expenditure

Expenditure on charitable activities decreased in 2025 to £40.9m (£48.5m in 2024).

In 2025, our spend across ‘Getting you new treatments, faster’ was £9.4m, (£17.7m in 2024). Both years reflect our strategic commitment as we invest reserves into our research programme, seeking to do all we can to increase the chances of significant breakthroughs in our understanding of, and treatments for, Parkinson’s.

We remain committed to providing better support every day, by investing in health and care professionals and our information and support services for the Parkinson’s community. Examples of these included our helpline, local advisers, information resources,

and volunteer-led support programmes, as well as ongoing campaigns to raise awareness of the condition and its impact. There are now over 90 Parkinson’s local advisers, and these services play a vital role in ensuring we’re there to support every Parkinson’s journey.

Following investment in growing our team and widening our service availability, nearly all roles had been filled by the end of 2024, and so 2025 saw a significant reduction in vacancy levels across the charity. This in turn helped to ensure we achieve our spending targets and that we can deliver our plans for our community and our ability to raise awareness. This was further strengthened by investment in our brand, with a refreshed brand launched in early 2025.

Expenditure	2025	2024
Total spend on charitable activities	£40.9m	£48.5m
Getting you new treatments, faster (total for research into potential causes of and treatments for Parkinson’s) ¹	£9.4m	£17.7m
Parkinson’s Research Ventures and drug development programme (included in research total above)	£1.6m	£4.4m
Building your community of support (information and support services)	£17m	£16.1m
Pushing for excellent health and care (opportunities to increase public understanding of Parkinson’s)	£8.9m	£10.3m
Becoming fit for the future (including making it easier for people to get involved with the charity, transforming our finance and data systems and raising the money needed to fund our strategy)	£5.6m	£4.4m
Cost of raising funds (including trading, merchandising and investment management costs)	£11.8m	£11m
Total expenditure	£52.7m	£59.6m

Notes
1. Research total includes £0m (2024: £1.1m) deficit in associate research companies. See note 4(d) on page 83.

Reserves policy

We invest funds to sustain the growth of the charity, while retaining sufficient levels of available reserves to help achieve our charitable purpose.

Historically, we adopted a liquidity-based approach, which was sufficient to cover six months of operating expenditure and 12 to 24 months of research grants.

In 2024, the board of trustees approved a new approach more closely aligned to the risk associated with a number of key areas. This new approach better reflects the balance between holding sufficient reserves and ensuring we’re using the charity’s money promptly and efficiently to deliver our mission.

Our reserves requirement is now calculated as a series of risk-based reserves, which add up to create a lower limit. We then add a buffer of three months of staff costs to create an upper reserves target. Our aim is to keep our free unrestricted reserves within this range. We review the risks and recalculate the financial values, and therefore the lower and upper targets, on an annual basis alongside setting the next year’s annual budget.

We have identified the following risk-based reserves:

- **Income risk reserve:** this is designed to protect the charity from unexpected falls in our income.
- **Cessation risk reserve:** this is an amount of money set aside to cover costs in the highly unlikely event that the trustees have to close the charity. It exists to ensure we’re being responsible and can pay any unmet costs, should the worst happen.
- **Infrastructure reserve:** this relates to our strategic pillar ‘Becoming fit for the

future’. We’re making sure we have the infrastructure we need now and into the future. This reserve protects this vital work.

- **Opportunity reserve:** this ensures some of our vital longer-term charitable programmes can continue if our financial position were to deteriorate. Some programmes, like our research grants and our nurse post funding, take time to develop, and a sudden cut in funding would be damaging to the research community or the pipeline of Parkinson’s nurses. We’ve therefore set aside funds to help us continue these activities if our finances become strained.
- **Working capital reserve:** our policy is to ensure we have cash of at least £5m available at any given time, to make sure we can pay our suppliers, staff, and partners on time. Our treasury management policy sets out how we manage this, and our reserves policy includes a reserve to take account of this requirement.

- **Investment risk reserve:** we hold investments to ensure we are able to maximise the value of the unspent funds we hold. This includes where we have long-term funding commitments, like research grants. We therefore hold a reserve to protect the charity from sudden variations in investment values.

This equates to a lower limit reserves target in 2025 of £18.4m (2024: £17.8m) and a higher limit reserves target of £25.7m (2024: £24.8m) which would be sufficient to cover operational expenditure for four to six months.

This excludes designated cash holdings set aside for our local groups.



Walk for Parkinsons, Battersea, 2025

From the current available reserves, the board agreed to increase strategic investment projects to support achieving better outcomes for people with Parkinson's from 2024 to 2026. Some of this had been set aside in designated funds.

In 2024, to improve the transparency of how we use our reserves, the board agreed to set aside ("designate") the funds which exceed our upper reserves target, so that these funds can be shown separately in our accounts and to make it clear that our intention is to bring reserves into line with our new target by the end of 2027. This fund is referred to as the Every Parkinson's Journey Fund. Of this, £19.7m remains to be spent as at 31 December 2025 (2024: £22.9m).

Total unrestricted funds at the end of the year were £52.6m (2024: £53.7m). After deducting the designated funds of £19.7m and £7.9m for local groups, the remaining reserves amounted to £25m, compared to £22.8m in 2024. The liquid reserves at 31 December 2025 are £24.7m (2024: £21.2m).

Investment policy and returns

During 2025, the investment objective for the long-term investment portfolio was to generate a total return of inflation (CPI) plus 2-3% per annum net of fees over a five to seven year investment period. The precise Target Return agreed with the discretionary investment manager depends on market conditions, the distribution requirements of

the charity, analysis of acceptable risk/return and advice from the appointed investment manager.

The Target Return is to be reviewed on at least an annual basis by the Investment Committee established by the board. This allows the charity to aim to at least maintain the real value of the assets over time, while making a contribution to the charity's annual expenditure when appropriate. As a general principle, up to 2% per annum should be contributed to the charity from the long-term investment portfolio, to support the charity's activities.

The charity believes that, in investing its funds, due consideration must be given to environmental, social and governance issues: see also pages 57 to 58. Our policy is designed to enable a responsible investment approach, while minimising any potential negative impact on our investment returns.

On 31 December 2025, the market value of the charity's investment portfolio was £36m (2024: £36.1m), held within three investment portfolios. Of this, £34.9m was actively managed by JP Morgan in a segregated 55% equity and 45% fixed income discretionary portfolio (90% allocation to the multi-asset portfolio and a 10% allocation to a segregated equity portfolio), a further £10.9m in an asset liability matched bond portfolio (also managed by JP Morgan) and £3.2m placed in a fund actively managed by Troy Asset Management (the Trojan Ethical Fund).

During 2025, the investment portfolio generated income of £870,000 (£862,000 in 2024) and a net gain of £1.7m (£2.1m gain in 2024).

The Investment Committee regularly reviews the performance of our investments and the credit ratings for the financial institutions holding our deposits. Performance of the JP Morgan portfolio is measured against a benchmark of 55% MSCI World Net GBP and 45% Bloomberg Global Aggregate hedged GBP. The Trojan Ethical Fund's performance is benchmarked against the UK Retail Prices Index.

The target for investment returns is to outperform these benchmarks. The portfolio managed by JP Morgan continues to provide returns yet the overall annual position was below the benchmark. We're continuing to review and monitor that position. The portfolio managed by Troy continued to perform well and exceeded the benchmark. The board is satisfied that investments have been appropriately managed and monitored during the year, in line with our investment and treasury management policies. Those policies are reviewed annually to ensure they remain fit for purpose.

Going concern

The board has reviewed our financial position and believes there are sufficient resources to manage any operational or financial risks. Throughout the year the board receives financial updates on our spend against budget and the performance of our investments.

We had very high levels of reserves against our policy due to the sale of 215 Vauxhall Bridge Road in 2022 and our delay in spending against our strategic plans. We are now on track to spend down our reserves

in the next two years, which will still leave us in an excellent position to navigate any uncertainty ahead. Our risk-based reserves policy ensures we maintain a level of reserves that balances the need to spend donors' money promptly and the need to remain financially sustainable in the long term, for as long as we are needed.

The board reviewed the charity's fundraising trajectory in 2024 and endorsed a strategy focusing on accelerating revenue generation. Our recent performance suggests that this investment is bearing fruit now and will continue to do so in the future.

We reasonably expect that we have adequate resources to continue operating for the foreseeable future and no material uncertainties have been identified.

The board is satisfied that there are no material uncertainties relating to events or conditions which may cast doubt upon the Group's ability to continue as a going concern and therefore continues to adopt the going concern basis of accounting in preparing the annual report.



Par-Con, Birmingham, 2025

An ethical and effective organisation

Our values

People-first

We're a strong movement for change, informed, shaped and powered by people affected by Parkinson's. We value and support each other.

Uniting

We're scientists and supporters, fundraisers and families, carers and clinicians. We're working, side by side, to improve the lives of everyone affected by Parkinson's.

Pioneering

We innovate across everything we do. Creative, courageous and with pioneering spirit, we strive to continually improve.

Driven

We live and breathe our purpose. We set clear goals and strive to deliver the greatest impact for everyone affected by Parkinson's.

Parkinson's UK is all about people...

We are a powerful community of people, and our work is driven by the needs of people with Parkinson's and of those who love and care for them.

Staff and volunteers

People and Culture Strategy

We launched our People and Culture Strategy setting out our vision for the experience of our people (staff and volunteers). Our strategy is built on three themes:

- **Making things easier for our people:** making our systems and processes easier to use for both staff and volunteers.
- **Engaging and leading together:** prioritising activities, ensuring alignment on decisions and modelling an inclusive culture.

- **Enriching our experience:** continuously developing our volunteer journey and our offer for staff.

We restructured the People and Culture directorate to be in the best position to support the charity to deliver our Strategy and realise our People Vision.

Delivering our People and Culture Strategy included:

- introducing a community engagement initiative for staff to spend one working day connecting with the Parkinson's community, enabling colleagues to learn more about Parkinson's to apply in their roles
- implementing a new intranet and regular communications from our Executive Leadership team, to make it easier for staff to stay connected and share news, information, events and inspiration



Royal Parks Half Marathon, 2025

- hosting our first all-colleague event, bringing together over 600 colleagues to continue to nurture a sense of belonging and to celebrate excellence
- offering 360° feedback for our senior leaders to enable them to engage and lead our people consistently, and continue their personal development
- developing toolkits to support colleagues who recruit and manage volunteers, covering volunteer recruitment and data management
- building on our internal leadership development course, Management Essentials, and launching a new pilot.

Volunteers

Our dedicated and talented community of volunteers plays a vital role in helping us achieve our mission. Our volunteers are involved in research, leading local groups, facilitating Newly Diagnosed sessions, educating health and care professionals, campaigning to make change for the Parkinson's community and raising funds to support our work. Thank you to the 4,250 volunteers who gave us their time in 2025. We couldn't do what we do without you.

Volunteer comms and engagement

Keeping all of our volunteers engaged with the information they need in their roles and the work we're doing as a charity is a

key part of helping them be as effective as possible. To do that, we share updates with volunteers through weekly articles on our volunteer management system and our All Volunteer Calls. We also have team-specific communications for group volunteers, campaign volunteers and research volunteers.

Volunteering representation

The Volunteering Steering Group consists of up to 10 volunteers who live in different parts of the UK and hold various roles within Parkinson's UK. The role of the Group is to shape projects, policies and resources for volunteers and colleagues to ensure we provide a good volunteering experience and make an impact for people with Parkinson's.

In 2025 we established a Volunteer Recruitment Task and Finish Group to improve our volunteer recruitment process and marketing. We are updating volunteer role descriptions, developing a recruitment toolkit for volunteers and reviewing our volunteering advertisements.

Volunteer learning

In keeping with our goals around safeguarding, we relaunched our Keeping People Safe sessions for volunteers, which support volunteers to identify and report safeguarding concerns.

We also began scoping new streamlined volunteer learning pathways for induction, to further increase engagement for and

investment in our volunteers. We want all of our volunteers to feel safe, comfortable, and prepared for their roles to help them make the biggest impact in their roles.

Equity, diversity and inclusion

We remain committed to growing our culture of belonging so that we can be there for every Parkinson's journey. The needs of our community are central to our work, and we have recently revised our strategy to move beyond a 'one size fits all' approach. We now focus on equity – offering the right support at the right time – because we recognise that different groups face unique barriers.



Zarka, research participant, with a Parkinson's UK employee

Our revised EDI strategy is built upon four strategic pillars:

- **Inclusion for our community:** creating a space where everyone in the Parkinson's community feels they belong and are valued.

- **Tackling inequity faced by our community:** ensuring everyone can access the support and services they need so no one is left behind.

- **Inclusion for our people:** building a workplace where colleagues and volunteers feel respected, included, and able to do their best work.

- **Tackling inequity faced by our people:** standardising processes to ensure equitable access to career growth and support for all colleagues.

In 2024 and 2025, we made significant strides in making EDI central to our operations, including:

- **strengthened community connections:** we have improved the way our staff engage with the community, with **72.5%** of colleagues now regularly connecting with the Parkinson's community as part of their work
- **evidence-based culture:** we completed a comprehensive review of colleague data and launched '**Stay Interviews**' to better understand the lived experiences, challenges, and motivations of our people
- **targeted support groups:** we successfully built upon our online network for **Black, Asian, Arab, and mixed heritage** individuals and are using these insights to respond to the information needs of other marginalised groups.

Staff remuneration

We pay a fair and appropriate salary to attract and retain the best people with the right management and leadership experience. As part of our commitment to openness, we disclose information about senior staff salaries in our financial statements and on our website.

All salaries, including those of the Executive Leadership team, are evaluated using an external benchmarking tool, Brightmine. This uses industry-wide sector comparison information based on charities of a similar size, impact and income. Our policy is to pay at the median level of the organisation's recommended scales.

Senior leadership and other senior salaries

The earnings of the chief executive, the Executive Leadership team and other senior staff who earn above £60,000 are disclosed in the financial statements.

Gender pay gap

As at 5 April 2025, our gender pay gap was:

- **8.9% median**
- **16.3% mean**

Compared with April 2024, the mean gender pay gap has increased by 2.0%, while the median has reduced by 2.7%.

Between April 2024 and April 2025, the mean salary of female leavers was £43,523.39, compared with £60,798.03 for male leavers. This represents a significantly wider difference than in the previous reporting year, when the variance was £549.74. In 2025, the difference increased to £17,274.64, reflecting the exit of a number of higher-paid male colleagues and reinforcing the sensitivity of the mean pay gap to relatively small changes at senior levels.

Over the same period, we onboarded 114 female employees, representing a 12% increase on the previous year (102 in 2024). Of these appointments:

- Four women joined the organisation in leadership roles: two associate directors and two heads of department

- Women accounted for 83% of all technical and specialist appointments
- Women also represented 77% of all management appointments.

Median gender pay gap (5 April 2025)



Ethnicity pay gap

As at 5 April 2025, our ethnicity data shows:

- **Ethnic minority colleagues earn on average £456.08 more than white colleagues**
- **This equates to a positive ethnicity pay gap of 1.05%**



The average salary for white colleagues is £43,479, compared with £43,935 for ethnic minority colleagues. This positive gap has increased slightly from 2024 and reflects a strong position relative to many organisations.

This is calculated slightly differently to the gender pay gap by taking the mean salary of all white and non-white employees and calculating the variance.

Median ethnicity pay gap



You can find information about our gender pay gap, ethnicity pay gap and the measures we're taking to address them on our website.

Safeguarding

Safeguarding is a core part of who we are and how we work. We have a duty of care to protect people with Parkinson's, their families and carers, and our staff, volunteers and wider community from harm, abuse and neglect.

We have a steadfast commitment to building and sustaining a strong safeguarding culture across the charity. This means ensuring everyone who represents us understands their responsibilities, feels confident to recognise signs and indicators of abuse or neglect, and

knows how to share concerns quickly so that appropriate action can be taken.

Through clear policies, robust procedures, mandatory and role-specific training and ongoing specialist advice, we prioritise the safety, dignity and wellbeing of everyone who comes into contact with us. Safeguarding is everyone's responsibility, and we will continue to strengthen our practice so that people with Parkinson's and their families and carers are kept safe from harm.

Our helpline acts as an easy to access resource, especially for time-sensitive issues, ensuring that people with urgent needs have a way quickly to receive support.

We're dedicated to strengthening and further developing our safeguarding approach in 2026. This includes a new pathway for volunteers, ensuring that safeguarding is an essential component of their induction and training.

As an organisation, we remain focused on continuous professional development so that everyone representing us has the knowledge, skills and confidence to safeguard effectively. We will continue to review and strengthen our training, policies and practice, learn from every concern raised, and work in partnership with others. In doing so, we aim to uphold and enhance our reputation as a safe, trusted place for people with Parkinson's, their families and carers, our staff, volunteers and wider community.

How we fundraise

We're committed to high standards in all areas of our work. We recognise that our supporters are often people who are affected by Parkinson's directly, either with a diagnosis, or as friends, relatives or carers. When fundraising, we aim to do so responsibly, appropriately and positively. Our fundraising leadership team, managers and staff take responsibility to ensure that fundraising activities meet expectations of standards and our organisational values. Often, fundraising activities meet other organisational goals to connect with and support the Parkinson's community.

Our common fundraising activities include: fundraising appeals by post, telephone, email or advertising; raffles and lotteries; fundraising events; partnerships with companies; applications for funding to trusts and foundations; community-based fundraising; cash collections; payroll donations; legacies from wills; and purchases from our online shop.

Fundraising can be carried out directly by staff or under their instruction. We work with third parties, including commercial organisations and professional fundraisers. We also have a large network of committed volunteers, including people with Parkinson's, who carry out fundraising in aid of or on behalf of the charity. Expectations are set and guidance given that a high standard of experience for supporters and the public is paramount in all fundraising interactions, whatever the outcome.

Our commitment to industry standards

We take seriously the need to comply with the industry standards, rules and regulations that govern all our fundraising and marketing activity. We ensure all staff adhere to, and instruct any third parties we work with to

adhere to, relevant codes, standards and regulations for any fundraising that they carry out on our behalf. We seek guidance where needed to ensure understanding and inform our decision making. Our audit process has disclosed no reportable breaches of the Code of Fundraising Practice or of any other fundraising regulatory standards in 2025.

Working with third parties

Where professional fundraisers are employed by us, they will have been awarded a contract on the basis of an appropriate tender process. Depending on the relationship between us and a third party, we will: conduct an appropriate level of due diligence; provide appropriate materials to support the fundraising; ensure that any relevant policies are understood and adhered to; give briefings, guidance, training and support to the fundraisers; make appropriate and compliant agreements or contracts with the third party; monitor the fundraising being carried out as appropriate and proportionate to the activity; and hold regular review meetings.

Protecting people in vulnerable circumstances


We are committed to ensuring that the needs of people in vulnerable circumstances are recognised and accounted for in how we conduct our fundraising. We endeavour to ensure that our representatives meet the requirements on behaviour within the Code of Fundraising Practice at all times. We recognise that many people who support or fundraise for us are those who themselves may have a diagnosis or be close to people with or have experienced the loss of someone with Parkinson's. We understand that vulnerability encompasses a wide range of circumstances and that those who are vulnerable may still wish to donate and may have capacity both financially and intellectually to make the decision to do so.

To ensure a responsible approach, we have a number of policies and procedures covering the actions we will take to identify and support people in vulnerable circumstances. We review the policies and processes of third party fundraisers to ensure that they are in line with our own approach. We have reporting mechanisms in place to make us aware of interactions where a person has been identified as vulnerable and the actions taken by the fundraiser. We are careful to respect the wishes of a person identified wherever possible in our actions and clarify our reasons for our decision making: for example, if we decide that someone should no longer receive fundraising approaches from us.

We accept that on occasion we and our representatives may not identify vulnerability or act flawlessly in an interaction. We will rectify any mistakes made by the donor or the fundraiser. We are committed to continual learning and improvement in how best to work with people in vulnerable circumstances and so keep our approach to vulnerability under review.

Feedback and complaints

We are continually improving processes to make sure everyone has the best possible experience when interacting with us. We value all the views and feedback shared by our community, and the public. We are committed to ensuring all feedback gets an appropriate and timely response. Our Supporter Care team co-ordinates feedback from a range of sources, including our website, email, telephone, post, and third parties. By encouraging, capturing and reviewing feedback, we gain insight into how people feel about the things we do as an organisation. It helps us improve individuals' experiences and make positive changes to the way we work.



In 2025, the charity received 92 complaints, representing 5.7% of feedback. This is compared to 109 complaints (7.5% of feedback) in 2024.

Of the 92 complaints received, 55 (59.8%) were specifically related to fundraising. This is a decrease from 66 (60%) fundraising-related complaints received in 2024.

The most common themes in complaints about our fundraising communications related to: specific email content; objecting to requests to participate in surveys; failure to meet expectations on removal from mailing lists; and feedback related to in memoriam donations (primarily issues relating to data processing via third party fundraising platforms).

Our feedback and complaints procedure is available on our website. For more information or any questions, please contact the Supporter Care team on **0800 138 6593** or email **supportercare@parkinsons.org.uk**.



Richard, living with Parkinson's,
Walking football Swindon, 2023

Setting ourselves up for success: Section 172 statement

Section 172 of the Companies Act 2006 requires the trustees to act in the way they consider, in good faith, would be most likely to promote the success of the charity to achieve its charitable purposes. As a membership charity we are accountable to our members, who support and engage with us. They challenge us to ensure that the decisions we make as a charity are for their benefit.

People with Parkinson's and the people who love and care for them are at the heart of our work. We are a values-driven organisation and our 'people-first' and 'uniting' values mean we are informed, shaped and powered by people with Parkinson's in all we do. We work with the Parkinson's community, scientists and supporters, fundraisers and families, carers and clinicians to improve the lives of everyone with Parkinson's.

Many illustrations of how we comply with the duty to promote the success of the charity are contained elsewhere in this report:

- Pages 22 to 30 summarise the most significant activities during the year to achieve our purposes.
- Pages 38 to 42 illustrate how we consider the interests of staff.
- Page 30 illustrates how we've improved our website to deliver more benefit to people with Parkinson's and to the charity.

In addition, the table below shows how the board of trustees has fulfilled its section 172 duties in taking several key decisions in 2025.

Key section 172 matters affected	Engagement, impact and long-term consequences
Significant decision/event: major expansion in, and launching an ambitious new plan for, our newly diagnosed offer	
The likely consequences of any decision in the long term. The impact of operations on the community, specifically people with Parkinson's and the people who love and care for them. The desirability of maintaining a reputation for high standards of business conduct.	We improved and expanded our resources for people newly diagnosed with Parkinson's and their loved ones, reaching far more people than ever before. As part of this we rolled out our pioneering Parkinson's Connect programme at 15 new sites across the UK. Find out more on page 29. Despite these achievements, we continue to hear from the community that for many people, the diagnosis journey is one they are forced to walk without our support and that of the wider Parkinson's community. So in 2025, we also launched a new No Diagnosis Without Support project. Our ambition for that project is that everyone receiving a Parkinson's diagnosis gets the information and support they need, when they need it, to live their best life with Parkinson's.
Significant decision/event: an improved operating model for Parkinson's UK groups	
The likely consequences of any decision in the long term. The impact of operations on the community, specifically people with Parkinson's and the people who love and care for them. The desirability of maintaining a reputation for high standards of business conduct.	Our network of groups are essential in delivering our strategy locally for people with Parkinson's. Our trustees delegate day-to-day management of groups to relevant group management committees, under what was formerly known as the "Local Group Operating Framework". The Framework presented several challenges for our group volunteers and their staff contacts. Following a thorough consultation exercise, we implemented a more clearly defined Framework, with core requirements which simplify governance and guidance for group volunteers. This makes it easier and more enriching to volunteer, delivering a more sustainable group structure with fewer volunteer recruitment challenges. Associated changes to membership rules clarify that we are all one charity working together to support the Parkinson's community.

Key section 172 matters affected	Engagement, impact and long-term consequences
Significant decision/event: a new People and Culture Strategy	
The likely consequences of any decision in the long term. The interests of the charity's employees. The impact of operations on the community, specifically people with Parkinson's and the people who love and care for them.	We implemented a new People and Culture Strategy to bring greater focus to the way we do things (our culture), and the role of our leaders to shape that culture. The Strategy sets out the vision for the experience of our employees and volunteers, aiming to make it easier, engaging and enriching for us to work together to make a difference in every Parkinson's journey. See also pages 38 to 39. Engagement in developing the Strategy included employee workshops, working with the Community directorate to hear from local group leads and hosting several "challenge and refine" sessions with staff and volunteers. We also took into account learnings from both staff and volunteer surveys.



Principal risks and uncertainties

Our aim is to mitigate risk exposure to an acceptable level across a broad spectrum of strategic and operational risk. We recognise that effective risk management is an important factor in the achievement of our strategic objectives and protecting the future sustainability of the charity.



We regard risk management as a key aspect of our governance arrangements and we follow the Charity Commission guidance.

Our board is accountable for the risk management arrangements at Parkinson’s UK. Trustees are committed to ensuring that the most significant risks to the charity, and to the achievement of our strategic objectives, are identified swiftly and effectively managed in line with our risk appetite.

Our board is supported by the Audit and Risk Committee, which reviews and makes appropriate recommendations to the board in relation to our risk management arrangements, and specific risks. The Committee scrutinises our most significant risks at regular intervals, to ensure the right risks are identified and that risks are being managed effectively and in line with our risk appetite.

Our internal auditor delivers independent and objective assurance advice, and provides insight into certain strategic risks annually through the internal audit programme, reporting to the Audit and Risk Committee.

Risks are managed at a commensurate level across Parkinson’s UK, with the most strategic risks being assigned to an Executive Director owner. Each risk owner is responsible for developing and delivering an appropriate risk response and mitigation plan, which will be scrutinised via an appropriate governance meeting.

For each risk, the likelihood is identified and the impact is assessed using both quantitative and qualitative information.

The principal risks monitored by the final Audit and Risk Committee in 2025 are set out on the next two pages, together with a summary of the control measures and mitigations employed as part of our plans and strategies for managing those risks over the course of the year.

We are committed to continuous improvement, and with this in mind, we undertook a review of our risk management arrangements during quarter one of 2026.

Risk description	Risk rating (post mitigation)	Controls and mitigations
We fail to respond effectively to a safeguarding incident due to inadequate internal controls. This may result in harm to staff, volunteers or clients.	Moderate	• Safeguarding policy and training • Recruitment checks (DBS) • Volunteer induction
Mismanagement of reputational issue.	Moderate	• Media training, and trained staff available 24/7 • Conflict of Interest Report • Gifts and Hospitality Report • Fraud Report • Culture Report
Financial and workforce pressures in health and social care could threaten the sustainable recruitment of new nurses and associated health professionals and challenge our ability to drive service improvements.	Moderate	• Complete Care for Parkinson’s Programme • Local campaigns • Recruitment drives
Inefficiency of financial processes could impact operational delivery.	Moderate	• Delegated Authority Policy • Scheme of Delegation • Investment Policy • Reserves Policy • General Procurement Policy • Treasury Management Policy • Investment Committee
A significant incident during a Parkinson’s UK-funded or endorsed clinical trial resulting in the death or severe injury of a participant.	Moderate	• Peer Review Panel • MHRA and Ethics Committee reviews • Safety testing • Delegated Authority Policy • Parkinson’s Research Ventures Governance Framework

Risk description	Risk rating (post mitigation)	Controls and mitigations
A reduction in income streams from fundraising channels due to external economic climate, increased competition for funding due to challenging financial positions of other national charities and loss of future income due to high reserves position coupled with excessive expenditure and draw down from our reserves could result in a liquidity crisis and impact our delivery of our strategy and services to our beneficiaries.	Moderate	- Fundraising campaigns - Delegated Authority Policy - Scheme of Delegation - Investment Policy - Reserves Policy - General Procurement Policy - Treasury Management Policy - Investment Committee
Failure to implement transformational change effectively could impact our ability to deliver services, raise income and ultimately negatively impact our reputation.	Moderate	- Investment Policy - Investment Committee - Project Management Function
Tech failure or serious data breach.	Moderate	- Data Protection and Data Security Policies, and training - Data Protection Officer, and Data Security Lead

The list of principal risks above and on the following page, and the risk ratings ascribed to each, has been reviewed and revised over the course of 2025. For example, "Major external change or shocks" and "Meeting the needs of service users and supporters" no longer appear as separate risks as they are now included within other risk descriptions. Risks around transformational change and cyber security, which were rated high in 2024, are now rated moderate due to improvements in our processes and governance.

Risk description	Risk rating (post mitigation)	Controls and mitigations
Volunteer attrition due to inadequate training/processes or other causes out of the control of the charity. Volunteers leave, feel unrewarded or disengage with our values resulting in challenges in the provision of services, reputational damage and recruitment.	Moderate	- Volunteering Policy, Agreement and Framework - Annual succession planning review
We fail to support our staff and volunteers and ensure they are aware of their health and safety responsibilities, which could have a negative impact on our people's health and wellbeing while they are working at the charity and various implications for the charity (i.e. financial/legal/reputational damage etc.).	Moderate	- Health and Safety Policy and training - Hybrid working arrangements - Employee Assistance Programme - Occupational Health Service - Risk Assessment process - Lone working policy, risk assessment process and alarm system - Culture Report
Potential benefits and adverse outcomes of AI technologies (including generative AI) on society or on the charity.	Moderate	Policies and guidelines
Loss of key personnel; failure to recruit and retain suitable workforce.	Low	- Notice periods - Diversity and Inclusion Policy - Learning and Development Line Management Programme - People and Culture team

Structure, governance and management

Parkinson's Disease Society of the United Kingdom was founded in 1969 by Mali Jenkins, whose sister had Parkinson's. The Society rebranded in 2010 and, since then, we have operated under our trading name of Parkinson's UK.

Parkinson's UK is a registered charity and a company limited by guarantee (see page 102). The charity also operates in Northern Ireland and has a branch in Jersey. The Group includes subsidiaries, details of which are on page 63.

This report of the trustees incorporates the strategic report and directors' report required under the Charities Act 2011 and the Companies Act 2006. It has been prepared in accordance with our governing document and the Statement of Recommended Practice (SORP 2019) "Accounting and Reporting by Charities".

The activities we carry out to further our charitable objectives (purposes) are for the public benefit. Our objectives are:

- to provide relief for people with Parkinson's and allied conditions, and to provide assistance, support and advice to people with Parkinson's and their families, dependents, friends, carers, and other persons affected by Parkinson's
- to promote and support research into the causes, prevention, treatment and cure of Parkinson's, and to disseminate the results of this research

- to advance the education of the public and health and social care professionals on issues relating to Parkinson's
- to promote any other charitable purpose for the benefit of people with Parkinson's and their families, dependents, friends, carers, and other persons affected by Parkinson's.

Board of Trustees

Details of our trustees are on page 102.

The board is responsible for the overall control and strategic direction of the charity, including approving the annual budget, and key organisational policies as well as defining the charity's risk appetite and monitoring the strategic risks the charity faces. The board met five times in 2025, with an additional ad hoc session and a discussion away day.

Committees support the work of the board. Day-to-day running of the charity is delegated to the chief executive, supported by the Executive Leadership team. A delegated authority policy and framework of delegation are in place to set out matters delegated to committees or to the Executive Leadership team.

The policy and framework are regularly reviewed. Conflicts of interest are considered annually and against the agenda of each meeting.

Our trustees give their time to Parkinson's UK on a voluntary basis and are not paid for the work they do. They may claim reasonable expenses for attending meetings or carrying out other duties.

Trustee election and recruitment

The board has a maximum of 14 members, comprising up to seven trustees elected by our members and up to seven trustees appointed by the board.

Elected trustee candidates must be members of the charity, fulfil the other eligibility criteria set out in our governing document and be nominated by two other members. Election is by ballot and all members living in the electing country are eligible to vote.

Appointed trustees are identified by a thorough recruitment and selection process. The criteria for selection of trustees includes the need to consider a range of skills and experience and recognises the importance

of diversity of experience and backgrounds in contributing to an effective board.

The criteria also recognise the importance of having people on the board with a connection to Parkinson's. The overall aim of trustee recruitment is to ensure there is an appropriate mix of skills and experience on the board and that we meet succession planning needs. As at December 2025, there were 13 trustees of whom 4 are people with Parkinson's, 7 are women and 1 is from a minority ethnic background.


The board's People Committee manages the process for appointing trustees and recommends candidates for approval by the board.

In seeking trustees, whether appointed or elected, we are committed to furthering equity, diversity and inclusion.

Trustees usually serve for a term of four years. People with Parkinson's who are concerned they may not be able to serve a four-year term are still eligible to stand for election. Trustees may serve for an additional term if successfully reelected or reappointed.

Trustees' induction and development

All new trustees undertake an induction programme in a format approved by the People Committee, including meetings with the chief executive, Executive Leadership team and other key staff. They receive detailed information and opportunities to build knowledge of the charity, including tailored induction sessions on a flexible basis according to individuals' needs. Additional and ongoing development is arranged as required for individual trustees or for the board as a whole.



Charity Governance Code statement

The board supports the principles of good governance set out in the Charity Governance Code and has reviewed, and will regularly revisit, our application of those principles and evidenced sources of assurances against them.

The board regularly undertakes a review of its effectiveness to identify any improvements to governance or any development needs.

An externally-facilitated governance and board effectiveness review was undertaken in 2025. The board reviewed the recommendations of the review in July 2025. A key recommendation, the establishment of an additional board committee, will be implemented in 2026. An internal review is scheduled for 2026.

Board and committee chairs build reflective dialogue into meetings throughout the year. This is to ensure the board and committees work effectively to make informed decisions through teamwork, using the appropriate balance of people's skills, experience, backgrounds and knowledge.

Board committees

The board delegates certain responsibilities and decision-making to its committees. Each committee has detailed terms of reference and reports regularly to the board.

Audit and Risk Committee

- Assists the board to ensure the charity has effective internal control and risk management systems in place.
- Oversees risk management framework and internal and external audit arrangements.
- Met three times in 2025.

Investment Committee

- Assists the board to ensure the charity has appropriate investment and treasury management policies.
- Monitors investment managers' performance.
- Met three times in 2025.

People Committee

- Oversees the charity's People and Culture Strategy and key related policies.
- Recommends any staff and Executive Leadership team remuneration increases to the board.
- Advises on board succession, election and recruitment requirements and oversees any election and recruitment activity.
- Oversees trustee induction, development and evaluation.
- Met four times in 2025.

Chairs of Board Committees Group (formerly the Executive Committee)

- Acts on behalf of the board on any urgent matter.
- Reviews and approves serious incident reports for submission to the Charity Commission.
- Met once in 2025.

Research grants and governance

The range of grants we made available to support Parkinson's researchers are key to the achievement of our "getting you new treatments, faster" objective. They included grants for projects, non-drug approaches and for senior research fellowships. We funded research through open competition and published details of our policy and application and review processes on our website:

parkinsons.org.uk/research/funding-grants/process.

To ensure the excellence of the research supported by Parkinson's UK, the research we fund is carefully evaluated by appropriate scientific experts and members of the Parkinson's community. All Parkinson's UK-funded research is subject to ongoing monitoring by the charity.

Research grants

The College of Experts is formed of scientific experts from all areas of Parkinson's research and additional areas of scientific technical expertise. The College of Experts is involved in reviewing grants from preproposal to full application and panel meeting phase. The College makes recommendations for funding for project grants, non-drug approaches and themed research schemes.

Lay grant reviewers are people with Parkinson's or a personal connection to Parkinson's. Reviews from lay grant reviewers allow us to incorporate their unique and valuable perspective into how we decide which projects to fund. This means that the needs and interests of people with Parkinson's are reflected in our research.

Parkinson's Research Ventures (formerly the Parkinson's Virtual Biotech)

Drug development projects seeking investment from Parkinson's Research Ventures are rigorously assessed by our in-house team with input from independent experts, including our Drug Discovery Advisory Panel and people with Parkinson's.

The Parkinson's Research Ventures Board, a group made up of industry professionals and experts with deep knowledge in the drug discovery and development process, guides our work by:



evaluating new research projects



advising on investment decisions



reviewing portfolio performance



suggesting new investment opportunities

Our non-research grants

Parkinson's UK made grants available for health and care services, individual professionals and students, physical activity advisors, and people with Parkinson's and their principal unpaid carers. Essential guidance was published on our website along with contact details of who could best advise on our criteria and processes.

Local groups

Our local groups fall under the governance and constitution of the charity. The board delegates certain responsibilities to their lead volunteers and committees using rules and guidelines.

Our community-led network of groups (including branches, support groups and cafes) are essential in delivering our strategy for people with Parkinson's. During 2025, we had 467 groups, cafes and online networks, including groups across the UK and the Channel Islands, and online networks for specific communities (for example, Black,

Asian, Arab and Mixed Heritage) or interests (for example, Deep Brain Stimulation). Our online Young Onset group also launched our first WhatsApp community, which quickly gained over 75 members.

These groups provide activities, mutual support and friendship to people with Parkinson's and the people who love and care for them. Group volunteers also carry out invaluable campaigning and fundraising for us, as well as supporting our work at a local level.



Together We Get Active campaign with those living with Parkinson's, 2024

Our ethical framework

We're determined to work consistently in the best interests of the Parkinson's community, and demonstrate openness and integrity in all our practices and decision making.

We're firmly committed to protecting the dignity, privacy and safety of everyone who gets in touch with the charity.

We think carefully about the health, social and environmental impact of our activities, partnerships, investments and funding, and how these reflect our mission to improve life with Parkinson's.



Environmental

- We laid the foundations to enable better understanding of our impact on the environment, so we can take more meaningful action in future. Emerging evidence of the potential links between Parkinson's and environmental factors, especially air pollution, gives us an added incentive to ensure we are acting responsibly and sustainably when it comes to the environment.
- We further strengthened our carbon footprint reporting during the year, thanks in part to the introduction of a new performance and impact function within the organisation. See more on pages 59 to 62.
- We began an assessment of the options for further reducing the environmental impact of our investments. This work will conclude in 2026.
- We continue to pursue initiatives that limit our direct emissions, and consider environmental policies when conducting large procurement activities.



Research participant living with Parkinson's, 2025

Social

- During 2025, we developed a new performance and impact framework, which will be refined through 2026 to align with our objectives for our next strategic period. This helps to ensure we focus on the impact we have for people with Parkinson’s, rather than just measuring activity.
- We are committed to growing our culture of belonging so we can be there for every Parkinson’s journey. The needs of the Parkinson’s community are central to our work.
- We focus on equity – offering the right support at the right time – because we recognise that different groups face unique barriers.
- We are determined to achieve inclusion for our staff and volunteers: building a workplace where staff and volunteers feel respected, included, and able to do their best work. Initiatives such as a multi-faith staff group and other affinity groups help to foster a sense of belonging.
- Our assessment of the gender and ethnicity pay gaps suggests we perform better than many of our peers, but we have some way to go to build on the progress already made.

Governance

- One of the most significant threats facing all charities is cyber crime. Our Audit and Risk Committee undertakes regular reviews of our approach in this area to ensure we do everything we practically can to keep the organisation safe. We have recently renewed our Cyber Essentials Plus accreditation and undertake regular training and awareness raising for staff. We are also reviewing ways to improve our technology offer for local groups, further increasing their cyber security capabilities.
- We ensure the participation of members of the Parkinson’s community in our decision making, including in research and in strategy development. This also extends to recruitment, where the generous input from people with Parkinson’s helps to ensure we recruit key staff who are aligned with our mission and values.
- We identify and manage risks to the delivery of our strategy, and undertake regular internal audit reviews across a range of activities to provide management and trustees with assurance over key risks. The internal audit programme adds significant value and is seen by both management and members of the Audit and Risk Committee as being a key tool for continuous improvement.
- During 2025, we undertook an independent review of our governance arrangements to identify areas of success to build on, and areas for improvement. This led to a revised board committee structure which will be implemented in 2026. The new structure is intended to enhance trustee and independent member oversight while ensuring our governance continues to be streamlined and efficient.



Streamlined energy and carbon reporting


The following table summarises our estimate of how much carbon dioxide was emitted in relation to our activities in 2025. Where data is available, we also include a comparable figure from 2024. A mix of supplier-provided data and greenhouse gas reporting conversion factors for various streams of CO2 production, as provided by the gov.uk website (2024 and 2025 respectively), were used to calculate these figures.

In 2025, we significantly expanded the scope of our carbon footprint measurement, including some Scope 3 emissions that had not been examined previously. This means that our 2025 carbon footprint is not directly comparable to previous years.

		Scope 1	Scope 2	Scope 3
		Gas	Electricity	Various*
Energy consumed (kWh)	2025	259,134	98,972	N/A
	2024	86,413	154,988	N/A
Government emissions conversion factor	2025	0.20229	0.20705	Various
	2024	0.1829	0.20705	Various
Emissions (tonnes of CO2)	2025	52	17	11,985
	2024	16	32	11,154
Performance indicator (staff numbers)	2025	585	585	585
	2024	534	534	534
Emissions ratio (tonnes of CO2/ staff member)	2025	0.09	0.03	20.49
	2024	0.03	0.06	20.89

*Investment portfolio, staff pensions, water consumption, home working, business travel, mail, cloud services.

2025 CO2 emissions by category



Scope 1

There is a gas boiler at 50 Broadway which heats the core of the building, including communal areas on each floor. The charity and other tenants are each responsible for paying a proportion of the total bill, determined by occupancy square footage. This forms part of our service charge.

Our managing agent has provided us with gas usage for the entire building, and we calculated our share based on occupancy square footage. In 2024, our consumption was instead estimated based on the average use for an office space of our size, leading to a significant difference between 2024 and 2025’s reported performance.

Scope 2

At 50 Broadway, the charity and other tenants are responsible for paying for the sub-metered electricity used within their demise, as well as a proportion of the total communal consumption determined by occupancy square footage. This forms part of our service charge.

Our managing agent has provided us with meter readings within our demise, as well as electricity usage for the entire building, and we have calculated our share based on occupancy square footage. In 2024, our consumption was instead estimated based on the average use for an office space of our size, leading to a significant difference between 2024 and 2025’s reported performance.

Scope 3

Our investment portfolio is by far the largest contributor to our carbon footprint (89%), followed by staff pensions, travel and home working. This is to be expected, given the profile of our activities.

Total emissions of 11,985 tonnes CO2 were made up of the following components:

Investments – 10,783 tonnes of CO2

We rely on our investment managers’ (JP Morgan and Troy Asset Management) ESG reporting for information on the carbon footprint of the funds we hold, and have calculated our footprint using the value of each fund on 31/12/2025. Our 2025 emissions remained broadly in line with 2024 emissions (10,920 tonnes), owing to a simultaneous increase in the value of the portfolio and a decrease of its carbon footprint per £1m invested.

Pensions – 660 tonnes of CO2

We rely on our pension provider’s (Aviva) ESG reporting for information on the carbon footprint of pension pots, as well as their assessment of the value of staff members’ pots in 2025.



Living well with Parkinson’s, Salisbury, 2025



Walk for Parkinson's,
Battersea, 2025

Travel – 278 tonnes of CO2

Our travel management company provides emissions data for the combustion of fuel for business travel purposes. This includes emissions relating to overnight stays in hotels and transport, such as flights and trains. Various conversion factors are applied depending on the type of service used.

Emissions from vehicles are calculated based on expenses claimed for employee-owned vehicles and on an internal log for taxi journeys. As data about the engine size and fuel type of vehicles is not available, CO2 emissions are calculated using the average car emissions conversion factor.

Our travel-related emissions in 2025 were broadly in line with 2024 (234 tonnes CO2). Given the small year-on-year difference and the level of uncertainty inherent to carbon footprint measurements, it's not possible to assess whether the carbon footprint of our travel is increasing or decreasing, but we note that prioritising rail over air travel remains an area for future improvement.

Home working – 262 tonnes of CO2

For the purpose of this calculation, we assumed that all home workers work from home 100% of the time, and hybrid workers work from home on days when they do not

have a desk booking logged on our system. Emissions were then calculated using the government conversion factor for home working.

Cloud services – 1 tonne of CO2

We rely on our cloud service provider's (Microsoft) ESG reporting for information on the carbon footprint of our Azure tenancy.

Water – 0.04 tonne of CO2

Our managing agent has provided us with water usage for the entire building, and we calculated our share based on occupancy square footage, using the water supply conversion factor.

Mail – 0.04 tonne of CO2

We hold an internal log of parcels and letters sent from our main office, and we rely on our supplier's (Royal Mail) ESG reporting to calculate their carbon footprint.



Subsidiaries and related parties

Subsidiaries



Parkinson's UK Sales Limited

Parkinson's UK Sales Limited carries out fundraising trading activities and sells products such as daily living aids, Christmas cards and general gift items. It donates all distributable profits to the charity.

Vivifi Biotech Limited

Vivifi Biotech Limited is a subsidiary of PRV. The PRV directors agreed in 2025 that it should be wound down.

Parkinson's UK Charity Limited

Parkinson's UK Charity Limited was established in, and has been dormant throughout, 2025.



Parkinson's Research Ventures Limited

The activities of Parkinson's Research Ventures Limited (PRV) include the commercial aspects of forming partnerships to fund research into better treatments and a cure for Parkinson's. Any taxable profits will be donated to the charity.

PRV's activities are financed through loans made by the charity under an unsecured loan facility, which bear interest at 1% above the Bank of England base rate (as disclosed in note 4).

The PRV board has devolved responsibility for selecting, reviewing and monitoring individual projects within an overall framework set by the charity board.

Note 4 to the financial statements summarises the results of the subsidiaries.

Related parties

Details of transactions with other related parties are in note 4 to the financial statements.



Parkinson's UK
merchandise, 2026

Statement of trustees' responsibilities

Trustees' responsibilities

The Trustees (who are also the directors of the charity for the purposes of company law) are responsible for preparing the Trustees' Report (including the Strategic Report) and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and charity and of the incoming resources and application of resources, including the income and expenditure, of the group and charity for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the applicable Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Financial statements are published on the charity's website in accordance with legislation in the United Kingdom governing the preparation and dissemination of financial statements, which may vary from legislation in other jurisdictions. The maintenance and integrity of the charity's website is the responsibility of the trustees. The trustees' responsibility also extends to the ongoing integrity of the financial statements contained therein.

The trustees confirm that they have taken account of the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives. They have also applied this to planning activities and strategy for the year ahead.

Directors' Statement as to the Disclosure of Information to Auditors

So far as each of the trustees at the time this report is approved are aware:

- a) there is no relevant audit information of which the auditors are unaware; and
- b) they have taken the steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees' Report, including the Strategic Report, was approved by the Board of Trustees and authorised for issue on 28 July 2026.



Gary Shaughnessy CBE
Chair of Board of Trustees



Royal Parks Half Marathon, 2025

Independent Auditor's Report to the members and trustees of Parkinson's Disease Society of the United Kingdom

Report on the audit of the financial statements

Opinion

In our opinion, the financial statements:

- give a true and fair view of the state of the Group's and of the Parent Charitable Company's affairs as at 31 December 2025 and of the Group's incoming resources and application of resources, and the Parent Charitable Company's incoming resources and application of resources, and the Group's and the Parent Charitable Company's cash flows for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006, as amended.

We have audited the financial statements of Parkinson's Disease Society of the United Kingdom ("the Parent Charitable Company") and its subsidiaries ("the Group") for the year ended 31 December 2025 which comprise the following:

- Consolidated statement of financial activities (Incorporating an income and expenditure account)

- Consolidated and charity balance sheets
- Consolidated cashflow statement
- Notes 1 to 23 to the consolidated financial statements including a summary of significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions related to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Group and the Parent Charitable Company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we

are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Other Companies Act 2006 reporting

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report, which includes the Directors' Report and the Strategic report prepared for the purposes of Company Law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic report and the Directors' Report, which are included in the Trustees' Report, have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatement in the Strategic report or the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- proper and adequate accounting records have not been kept by the Parent Charitable Company, or returns adequate for our audit have not been received from branches not visited by us; or

- the Parent Charitable Company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the Statement of Trustees' responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the Parent Charitable Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the Charitable Company and management.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations

Based on:

- Our understanding of the Group and the sector in which it operates;
- Discussion with management and those charged with governance;
- Obtaining and understanding of the Group's policies and procedures regarding compliance with laws and regulations;

We considered the significant laws and regulations to be the United Kingdom Accounting Standards, including the Revised Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice), UK tax legislation, the Companies Act 2006 and Employment law.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be the health and safety legislation, Charities Act 2011 and General Data Protection Regulations.

Our procedures in respect of the above included:

- Review of minutes of meetings of those charged with governance for any instances of non-compliance with laws and regulations;
- Review of correspondence with regulatory and tax authorities for any instances of non-compliance with laws and regulations;
- Review of financial statement disclosures and agreeing to supporting documentation;
- Review of legal expenditure accounts to understand the nature of expenditure incurred; and
- Review of Serious incident reports made to the Charity Commission.

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

- Enquiry with management and those charged with governance regarding any known or suspected instances of fraud;
- Obtaining an understanding of the Group's policies and procedures relating to:
 - Detecting and responding to the risks of fraud; and
 - Internal controls established to mitigate risks related to fraud.
- Review of minutes of meetings of those charged with governance for any known or suspected instances of fraud;
- Discussion amongst the engagement team as to how and where fraud might occur in the financial statements;
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- Review of internal audit reports; and
- Review of correspondence with HMRC, the Charity Commission for England and Wales and the Office of the Scottish Charity Regulator.

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls, and inappropriate legacy accrual.

Our procedures in respect of the above included:

- Testing a sample of journal entries throughout the year, which met a defined risk criteria, by agreeing to supporting documentation;

- Assessing significant estimates made by management for bias, including accrued legacy income; and
- Testing a sample of accrued and unaccrued legacy cases to ensure that income recognition is in line with the Charity SORP.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the Charitable Company’s trustees, as a body, in

accordance with the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the Charitable Company’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company, the Charitable Company’s members as a body and the Charitable Company’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Jill Halford

Jill Halford (Senior Statutory Auditor)
For and on behalf of BDO LLP, statutory auditor
London, UK

Date: 19 August 2026

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Financial statements

Consolidated statement of financial activities
(Incorporating an income and expenditure account) for the year ended 31 December 2025 (company no. 00948776)

	Notes	Group unrestricted funds £'000	Group restricted funds £'000	2025 Group total funds £'000	Group unrestricted funds £'000	Group restricted funds £'000	2024 Group total funds £'000
Income from:							
Donations and legacies		35,525	11,962	47,487	35,463	8,885	44,348
Charitable activities		52	151	203	12	320	332
Other trading activities		2,450	229	2,679	2,408	157	2,565
Investments		1,190	3	1,193	1,130	184	1,314
Other income sources:							
Other income		38	-	38	7	-	7
Total income	3	39,255	12,345	51,600	39,020	9,546	48,566
Expenditure on:							
Raising funds		11,304	3	11,307	10,544	1	10,545
Trading and merchandising		343	2	345	337	-	337
Investment management costs		187	-	187	201	-	201
Raising funds	7	11,834	5	11,839	11,082	1	11,083
Net incoming resources available for charitable application		27,421	12,340	39,761	27,938	9,545	37,483
Charitable activities							
Getting you new treatments, faster		2,740	6,695	9,435	11,489	5,138	16,627
Building your community of support		15,471	1,482	16,953	14,327	1,804	16,131
Pushing for excellent health and care		6,630	2,263	8,893	8,253	2,034	10,287
Becoming fit for the future		5,420	155	5,575	4,162	242	4,404
Share of deficit from associates		-	-	-	1,077	-	1,077
Total expenditure on charitable activities	7	30,261	10,595	40,856	39,308	9,218	48,526
Total expenditure	7	42,095	10,600	52,695	50,390	9,219	59,609
Net Expenditure before investment gains and losses	6	(2,840)	1,745	(1,095)	(11,370)	327	(11,043)
Net gain on investments	11	1,733	-	1,733	2,118	-	2,118
Net gain on revaluation of convertible loans	4	15	-	15	21	-	21
Net income/(expenditure)		(1,092)	1,745	653	(9,231)	327	(8,904)
Transfers between funds	16	5	(5)	-	2	(2)	-
Net movement in funds		(1,087)	1,740	653	(9,229)	325	(8,904)
Fund balances brought forward at 1 January	16	53,707	2,482	56,189	62,936	2,157	65,093
Fund balances carried forward at 31 December	16	52,620	4,222	56,842	53,707	2,482	56,189

All incoming resources and resources expended derive from continuing activities. The consolidated statement of financial activities include all gains and losses recognised in the year.

The deficit determined under the Companies Act 2006 (Net (expenditure)/income - Net gains/(losses) on investments) is £1,095,000 (2024: deficit £11,043,000).

Included within the group results are income of £52,889,000 (2024: £49,396,000), expenditure of £51,638,000 (2024: £51,039,000), and net movement in funds of £3,000,000 (2024: £487,000) resulting from the activities of the parent charity.



Pedal Trossachs, Scotland, 2025



Shake with Laughter, London, 2025



London 10K, 2025

Consolidated and charity balance sheets

as at 31 December 2025
(company no. 00948776)

	Notes	2025 Group £'000	2024 Group £'000	2025 Charity £'000	2024 Charity £'000
Fixed assets					
Intangible	10	1,260	915	1,260	915
Tangible	10	1,154	1,400	1,154	1,400
Investments and equity shares	11	36,177	36,370	35,969	36,149
Investments in subsidiaries and associates	11	-	-	25	25
Total fixed assets		38,591	38,685	38,408	38,489
Current assets					
Stock		79	50	-	-
Debtors - amounts falling due within one year	12	25,469	25,224	24,881	24,509
Cash at bank and in hand:					
- UK programmes		8,155	10,908	7,804	10,719
- Local groups		5,363	5,128	5,363	5,128
Total current assets		39,066	41,310	38,048	40,356
Creditors					
Creditors - amounts falling due within one year	13	(13,686)	(14,994)	(13,483)	(13,579)
Net current assets		25,380	26,316	24,565	26,777
Total assets less current liabilities		63,971	65,001	62,973	65,266
Debtors					
Amounts falling due after more than one year	12	-	-	24,203	20,593
Creditors					
Amounts falling due after more than one year	14	(7,129)	(8,812)	(7,129)	(8,812)
Net assets		56,842	56,189	80,047	77,047
Funds					
Unrestricted funds		25,016	22,885	48,223	43,743
Designated funds		27,604	30,822	27,602	30,822
Non charitable trading funds		-	-	-	-
Restricted funds		4,222	2,482	4,222	2,482
Total funds	16	56,842	56,189	80,047	77,047
Notes:					
Funds					
UK programmes		48,723	47,945	71,928	68,803
Local groups	5	8,119	8,244	8,119	8,244
Total funds	16	56,842	56,189	80,047	77,047

The financial statements were approved by the Board of Trustees and signed on its behalf by:

Gary Shaughnessy CBE
Chair of Board of Trustees
Date: 19 August 2026

Katrina Green
Trustee
Date: 19 August 2026

The accompanying notes form an integral part of these financial statements.

Consolidated cashflow statement

for the year ended 31 December 2025
(company no. 00948776)

	Notes	2025 Total funds £'000	2024 Total funds £'000
Cash flow from operating activities:			
Net cash (used in) operating activities	(a)	(4,508)	(2,771)
Cash flow from investing activities:			
Dividends and interest from investments		366	489
Purchase of intangible and tangible fixed assets		(942)	(1,978)
Proceeds from sale of investments		2,566	5,702
Purchase of investments		-	(2,112)
Net cash provided by investing activities		1,990	2,101
Change in cash and cash equivalents in the reporting period		(2,518)	(670)
Cash and cash equivalents at the beginning of the reporting period		16,036	16,706
Change in cash and cash equivalents due to exchange rate movements		-	-
Cash and cash equivalents at the end of the reporting period	(b)	13,518	16,036
Notes:			
(a) Net income/expenditure for the reporting period (as per statement of financial activities)		653	(8,904)
Adjustments for:			
Depreciation, amortisation and impairment		843	1,048
Loss on disposal of fixed assets		-	120
Share of deficit from associates		-	1,077
Gains on investments		(1,733)	(2,118)
Investment impairment		-	1,596
Dividends and interest from investments		(364)	(489)
Reinvested investment income		(829)	(825)
Investment manager fees charged to capital		187	201
Increase in cash at bank and in hand due to foreign exchange revaluation		-	-
(Increase)/ Decrease in stock		(29)	13
(Increase) in debtors		(245)	(784)
(Decrease)/Increase in creditors		(2,991)	6,294
Net cash (used in) operating activities		(4,508)	(2,771)
(b) Analysis of cash and cash equivalents			
Cash in hand		13,518	16,036
Overdraft facility repayable on demand		-	-
Total cash and cash equivalents		13,518	16,036

	At 1 Jan 2025 £'000	Cash flows £'000	Other changes £'000	At 31 Dec 2025 £'000
(c) Analysis of changes in net debt				
Cash at bank and in hand	16,036	(2,518)	-	13,518
Current asset investments	-	-	-	-
Total changes in net debt	16,036	(2,518)	-	13,518

Notes to the consolidated financial statements

for the year ended 31 December 2025

1. Charity information

Parkinson's Disease Society of the United Kingdom (known as Parkinson's UK) is a private company limited by guarantee (registered number 00948776), which is a public benefit entity and registered as a charity in England and Wales (Charity number 258197), and Scotland (SC037554), and domiciled in the UK. Its registered office is 50 Broadway, London, SW1H 0DB.

2. Accounting policies

Basis of accounting

The financial statements have been prepared in accordance with the Charities SORP (FRS102) applicable to charities preparing their accounts in accordance with FRS102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Charities Act 2011, the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006, as amended, and UK Generally Accepted Practice as it applies from October 2019. The charity has taken the exemption from presenting its unconsolidated SOFA under section 408 of Companies Act 2006.

Parkinson's UK meets the definition of a public benefit entity under FRS102. The financial statements have been prepared under historical cost convention with the exception of investments which are reported at market value.

Basis of consolidation

The financial statements of Parkinson's UK (including its branches and support groups), and trading subsidiaries, Parkinson's UK Sales Limited (registered number 1575175), Parkinson's Research Ventures Limited (registered number 11228595) and Vivifi Biotech Limited (registered number 13132805)

are consolidated, on a line by line basis, to produce the Group financial statements. In addition investments in associates, listed in note 4, are measured using the equity method. The consolidated entity is referred to as "the Group".

Going concern

The Board of Trustees has reviewed Parkinson's UK's financial position and believes that there are sufficient resources to manage any operational or financial risks. The ability of the Group and charity to generate funds has been better than projected in light of the continuing inflation levels and the cost of living crisis.

In conjunction with the board, the management team managed our cost base prudently in 2025. Combined with our income holding up well despite the macroeconomic challenges, the Group and charity expects to maintain a level of reserves within its defined operating range. The Group and charity have built up its liquid reserves in recent years and there are currently sufficient reserves to manage the Group and charity through any current uncertainty and provide support to the trading subsidiaries of the Group as set out in the relevant funding agreements.

In February 2024 the board took the decision to enable an orderly close-down of Vivifi Biotech Limited. This decision does not impact the going concern basis of the Group and Charity and further details can be found in note 4.

The board has reviewed cashflow projections covering several future years and there is a reasonable expectation that the organisation has adequate resources to continue in operational existence for at least 12 months from the date of signing of these accounts. The board is satisfied that there are no material uncertainties relating to events or conditions which may cast doubt upon

the ability to continue as a going concern and therefore continues to adopt the going concern basis of accounting in preparing the accounts.

Local groups

Local groups are required to operate under the charity's financial rules and to present unaudited accounts to their members at respective annual general meetings and submit an annual financial return to the charity's finance department. The income, expenditure and assets of local groups are set out in detail in note 5 and are included in the charity's results on a line by line basis. Larger value returns, typically those with income or closing balances over £25,000, are subject to an independent examination process.

Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, which are described in note 17, trustees are required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects the current and future periods.

The management team have undertaken extensive reviews assessing estimates made in the 2025 accounts, particularly around legacy income to provide some additional assurance that there are not likely to be any material changes which could affect the 2026 accounts. Therefore in the view of the trustees, no assumptions concerning future estimated uncertainty affecting assets and liabilities at the balance sheet date are likely to result in a

material adjustment to their carrying amounts in the next financial year.

Funds

Unrestricted funds are funds which are expendable at the discretion of the trustees in furtherance of the charity's objectives and include those funds set aside for programmes of work via the use of designated funds.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each of the charity's funds is further explained in note 16.

Income

All income is included in the statement of financial activities when the charity is legally entitled to the income, the amount can be measured with reasonable accuracy and its receipt is probable. When income is received in advance of providing goods or services, it is deferred until Parkinson's UK becomes entitled to the income. Legacy income is recognised when three criteria are met:

- Entitlement is established, receipt of the income is probable and it can be reliably measured.
- Entitlement is established when we receive notification of an interest in an estate and probate is granted
- Receipt of income is probable and measurement criteria is considered met when the statement of assets and liabilities is received.

Only when these criteria have been met is income from legacies recognised in the financial statements. Given the uncertainty which remains on legacy income until final estate accounts are received, a reduction is applied to legacy accruals. The reduction is calculated based on the expectation of estate management fees and any other uncertainties. The reduction is assessed on a case by case basis, but on average

the amount of the reduction is equivalent to approximately 5% depending on the circumstances of the legacy. Life interest gifts are only valued once legal title has passed to the charity and contentious cases are generally not recognised due to the level of uncertainty that arises.

Trading income is recognised at the point of sale. Investment income is accounted for on a receivable basis. A valuation of volunteer time is not included in the financial statements of the Group and charity.

Grants

Grant income from central and local government (whether grant or contract income) is detailed in note 20. For relevant grants, income is accounted for as the charity earns the right to consideration by its performance. Where the grant is received in advance of performance, its recognition is deferred and included in creditors. Where entitlement occurs before the grant is received, it is accrued in debtors. Grants received for a specific purpose are accounted for as restricted funds.

Resources expended

Expenditure has been classified by reference to specific activity categories: all direct costs relating to a specific activity have been aggregated; costs of raising funds include all direct fundraising expenses and an apportionment of support costs. All direct expenditure in furtherance of the charity's objectives, together with an apportionment of support costs, is included under the charitable activities heading. The bases of allocation of support costs are reviewed regularly and are explained in detail in note 7(b). When redundancy costs arise, they are charged in the period in which the charity becomes committed to incurring the costs and allocated on the same basis as other expenditure.

Grants to third parties for specific activities are charged in the accounts when an award

is approved by the relevant award panel, or when performance related grants' conditions are met, although disbursement of the funds may be made in subsequent accounting periods.

Financial instruments

Financial assets and financial liabilities are recognised when the Group becomes party to the contractual provision of the instrument. At the start of 2025 the Group had both basic and complex financial instruments. Basic financial instruments comprised of cash at bank and in hand, short term deposits and the group debtors excluding prepayments. Complex financial assets comprised of convertible loan contracts and these were measured at fair value at the balance sheet date using a number of assumptions to value the asset.

In 2023 the Group entered into two convertible loan contracts with a third party biotech company (EndLyz Therapeutics) for research purposes. In 2024 the Group entered into an additional convertible loan contract with EndLyz Therapeutics and a convertible loan contract with Acurex Biosciences Corporation, which was reviewed and subsequently written down to nil in the 2024 Accounts. The remaining convertible loans are carried in the accounts at fair value and are included in debtors. As inflection points have been met in these investments, a fair value adjustment has been conducted in line with the treatments outlined in the accounting estimates and judgements, note 17.

Financial liabilities comprise the Group's short and long term creditors excluding deferred income.

Cash at bank and in hand is held to meet short-term cash commitments as they fall due and includes all cash equivalents held in the form of short term deposits.

Trade and other debtors are recognised when amounts are due to the Group. Creditors and

provisions are recognised when the Group has a legal obligation to transfer funds as a result of past events that can be reliably measured or estimated and will probably result in transfer of funds.

No discounting has been applied to these basic financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including the investment portfolio and convertible loans with third parties, are held at fair value using the bid price at the balance sheet date, with gains and losses being recognised within income and expenditure. Investments in subsidiary undertakings is held at cost less impairment.

Leasing

Operating lease rentals are charged to the statement of financial activities over the period of the lease on a straight line basis.

Tangible fixed assets and depreciation

Tangible fixed assets are included at cost and are stated net of depreciation and any provision for impairment. Assets below the value of £2,000 are not capitalised except for computer equipment.

Depreciation is provided to write off the cost of tangible fixed assets over their useful economic lives on a straight line basis and it is charged across all activities as part of support costs. The annual rates used are:

Leasehold improvements – over the term of the lease	20%
Office equipment and fixtures	15%
Computer hardware	33.3%

Intangible fixed assets

IT software and website development costs have been capitalised within intangible assets as they can be identified with specific projects

anticipated to produce future benefits. Once brought into use, they are amortised on a straight line basis over the anticipated life of the benefits arising from the completed project. Currently the rate of amortisation is 33.3% per year and it is charged across all activities as part of support costs.

Fixed asset investments

Stock exchange listed investments are held at fair value using the bid price at the balance sheet date. Net realised and unrealised gains and losses in the year are included in the statement of financial activities. Cash deposits not expected to be utilised within 12 months are included in fixed asset investments and are stated at cost. The investment in the trading subsidiaries of £25,000 for Parkinson's UK Sales Limited, £1 for Parkinson's Research Ventures Limited, and £1 for Vivifi Biotech Limited are also stated at cost. The equity investments in EndLyz Therapeutics are stated at cost, and revalued for exchange differences at the year end. In 2024, both investments in Lucy Therapeutics and Acurex Biosciences Corporation were written off to a nil value in the accounts. On group consolidation the investments in NRG Therapeutics Limited and Keapstone Therapeutics Limited have been measured using the equity method.

Stock

Stock comprises goods for resale and is valued at the lower of cost and net realisable value.

Current asset investments

Current asset investments are cash deposits which are expected to be utilised within 12 months and are stated at cost.

Taxation

Parkinson's UK is a registered charity and is exempt from taxation on its income and gains to the extent that they are applied to its charitable purposes. The charity's subsidiaries, Parkinson's UK Sales Limited, Parkinson's Research Ventures Limited, have

not incurred tax charges in the period due to their policies of paying their taxable profits to the charity under Gift Aid. Vivifi Biotech Limited has not incurred tax charges on the basis of recording an operating loss for the period. Under a group VAT registration members of the group are eligible to recover VAT charged on expenditure based on the taxable supplies of income it supports.

Pensions

Parkinson's UK operates a defined contribution pension scheme. The cost of the defined contribution scheme is charged to the statement of financial activities in the year to which it relates.

Foreign exchange

Foreign currency grant commitments and payments are recorded at the exchange rate at the time of transactions. Foreign currency outstanding commitments are translated into sterling at the exchange rate at the balance sheet date. Foreign exchange gains are recognised as other income and foreign exchange losses are recognised in the consolidated statement of financial activities within the relevant charitable activity expenditure for the period in which they are incurred.

3. Income from:

	Notes	Group unrestricted £'000	Group restricted £'000	2025 Group Total £'000	Group unrestricted £'000	Group restricted £'000	2024 Group Total £'000
a) Income from donations and legacies							
Legacies		20,803	4,656	25,459	21,338	2,687	24,025
Donations and membership		14,722	7,306	22,028	14,125	6,198	20,323
		35,525	11,962	47,487	35,463	8,885	44,348
b) Income from charitable activities							
Grants	20	52	151	203	12	320	332
		52	151	203	12	320	332
c) Income from other trading activities							
Trading and merchandising		416	-	416	444	-	444
Other fundraising		2,034	229	2,263	1,964	157	2,121
		2,450	229	2,679	2,408	157	2,565
d) Income from investments							
Interest on deposits held by							
UK programmes		143	-	143	17	182	199
Local groups		187	3	190	144	2	146
Interest on convertible loans		-	-	-	107	-	107
Income from investments	11						
Managed funds		816	-	816	825	-	825
Cash held in managed portfolio		44	-	44	37	-	37
		1,190	3	1,193	1,130	184	1,314
e) Income from other income sources							
Other income		38	-	38	7	-	7
		38	-	38	7	-	7
Total income		39,255	12,345	51,600	39,020	9,546	48,566

4. Trading activities of subsidiaries and associates

a) Parkinson’s UK Sales Limited

The charity owns the entire share capital of Parkinson’s UK Sales Limited, incorporated in England and Wales. This company is responsible for the generation of income through various commercial activities for the financial benefit of the charity.

Summarised financial results for 2025 and the position of Parkinson’s UK Sales Limited at 31 December 2025 were:

Profit and loss account	2025	2024
	£’000	£’000
Turnover	504	544
Cost of sales	(434)	(423)
Gross profit	70	121
Interest receivable	1	7
Operating profit	71	128
Administrative expenses	(65)	(125)
Net profit for the year before Gift Aid donation to the charity	6	3
Gift Aid donation to the charity	(6)	(3)
Net profit for the year	-	-
Balance sheet		
Current assets	427	232
Creditors – amounts falling due within one year	(402)	(207)
Net current assets	25	25
Net assets	25	25
Share capital	25	25
Profit and loss account	-	-
Shareholders’ funds	25	25

b) Parkinson’s Research Ventures Limited

The charity owns the entire share capital of Parkinson’s Research Ventures Limited, incorporated in England and Wales. This company is responsible for the furtherance of the search for improved treatments and a cure for Parkinson’s and generation of income through commercial research activities for the financial benefit of the charity.

Summarised financial results for 2025 and the position of Parkinson’s Research Ventures Limited at 31 December 2025 were:

Profit and loss account	2025	2024
	£’000	£’000
Turnover	50	45
Cost of sales	(609)	(3,729)
Gross loss	(559)	(3,684)
Interest receivable	51	160
Gain on revaluation of convertible loans	15	21
Loss on revaluation of investments	(15)	(12)
Operating loss	(508)	(3,515)
Administrative expenses	(578)	(316)
Impairment of inter-company loan	(110)	(98)
Impairment of investment	-	-
Interest payable	(1,206)	(1,064)
Net loss for the year	(2,402)	(4,993)
Balance sheet		
Fixed asset investments	4,207	4,222
Current assets	776	764
Creditors – amounts falling due within one year	(12)	(1,223)
Net current asset/(liabilities)	764	(459)
Debtors – amounts falling due after more than one year	-	-
Creditors – amounts falling due after more than one year	(24,203)	(20,593)
Net liabilities	(19,232)	(16,830)
Share capital	-	-
Profit and loss account	(19,232)	(16,830)
Shareholders’ deficit	(19,232)	(16,830)

The directors of Parkinson’s Research Ventures Limited have assessed that with the wind down of Vivifi Biotech Limited and ceased activity, the inter-company loan balance, of £1,078,306 as at 31 Dec 2025 due from Vivifi Biotech Limited, is irrecoverable and has been impaired in full.

The Shareholders’ deficit as at 31 December 2025 does not present a concern to the board of trustees and directors of Parkinson’s Research Ventures Limited. The company is backed by an unsecured loan facility from the charity and the board of trustees have committed not to seek repayment of the loan until at least the end of 2028. The board of trustees and directors are satisfied that the activities in which the company is invested will have a reasonable likelihood of yielding financial returns in the long term to the charity.

c) Vivifi Biotech Limited

Parkinson’s Research Ventures Limited owns the entire share capital of Vivifi Biotech Limited, incorporated in England and Wales. The registered office changed on 29 August 2024 to 50 Broadway, London, SW1H 0DB. This company is responsible for the generation of income through commercial research activities for the financial benefit of the charity.

Summarised financial results for 2025 and the position of Vivifi Biotech Limited at 31 December 2025 were:

Profit and loss account		
	2025	2024
	£’000	£’000
Turnover	37	4
Cost of sales	-	(53)
Gross profit/(loss)	37	(49)
Administrative expenses	(48)	(53)
Interest payable	(51)	(53)
Net loss for the year	(62)	(155)
Balance sheet		
Current assets	32	14
Creditors - amounts falling due within one year	(1,088)	(1,008)
Net liabilities	(1,056)	(994)
Share capital	-	-
Profit and loss account	(1,056)	(994)
Shareholders’ deficit	(1,056)	(994)

In February 2024, the board of Parkinson’s UK took the decision to authorise Parkinson’s Research Ventures Limited to provide only such limited funding (as a loan) as would be required for an orderly close-down of the business. The directors expect that the company will cease trading by December 2026. The directors therefore do not consider it appropriate to adopt the going concern basis of accounting in preparing the financial statements. As a result, the Company will remain a private company until such time as the liquidation has been finalised. The financial statements have been prepared on a basis other than that of going concern. No adjustments were required to the financial statements following this change to the basis of preparation.

d) Associates

Associate	Principal activity	Class of share	Holding %	Investment £’000	Share of surplus	Share of surplus/ (deficit)
					2025 £’000	2024 £’000
Keapstone Therapeutics Limited The Innovation Centre, 217 Portobello, Broomhall, Sheffield S1 4DP	Research and experimental development on biotechnology	Ordinary	-	-	-	-
NRG Therapeutics Limited Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, SG1 2FX	Research and experimental development on biotechnology	Ordinary and preference	9%	4,001	-	(1,077)
Aggregate capital and reserves					2025	2024
					£’000	£’000
Keapstone Therapeutics					(175)	(159)
NRG Therapeutics Limited					7,126	3,191
					6,951	3,032

In 2017 Parkinson’s UK agreed a partnership with a biotech company called Keapstone Therapeutics Limited. As of 2025, we no longer have an interest and therefore there is a £nil recognition against Keapstone as an Associate, as opposed to previous years where we had a Director position and a 40% shareholding leading to us recording any attributable gains or losses (2024: loss £12,183).

In 2019 Parkinson’s UK agreed a partnership with a biotech company called NRG Therapeutics Limited. Parkinson’s UK had a warrant option to purchase 67% of the share capital of NRG Therapeutics Limited which it could exercise based on a number of exit events. In June 2022 the warrant was exercised by Parkinson’s Research Ventures Ltd with convertible loans of £1.5m. The loans were converted into equity in June 2022 and the equity investment is included in note 11. Within 2024 Parkinson’s Research Ventures Limited invested an additional £0.5m in NRG Therapeutics Limited, leading to a 24.1% stake. In a following investment round in 2025, Parkinson’s Research Ventures Limited chose not to invest any further which diluted that shareholding to just above 9%. Accordingly, as we no longer exercise significant influence, there is a £nil recognition for NRG Therapeutics Ltd as an Associate with these accounts.

5. Financial returns of local groups

The charity carries out a number of its charitable activities through a nationwide network of local groups, which raise income sufficient to fund their activities and, in most cases, also contribute to the funding of UK programmes.

The charity’s local groups produce independently examined accounts or finance returns annually. All local groups submitted financial information for 2025, with four exceptions (2024: six) for whom last reported balances are included. The impact of these omitted groups is not considered material to the results of the charity.

Income and Expenditure	Notes	2025	2024
		£’000	£’000
Total income	(a)	4,015	4,003
Total expenditure	(b)	(3,398)	(3,161)
Net movement in funds		617	842

Application of net funds raised by local groups:

Transfers to UK programmes for:		
Getting you new treatments, faster	(215)	(349)
Building your community of support		
– Local activity	(10)	(7)
– Service improvement and education	(423)	(56)
– Information and support	(4)	(76)
General and other activities	(90)	(110)
Total net resources transferred	(742)	(598)

Net movement in funds retained by local groups after transfers	(125)	244
--	-------	-----

Fund balances brought forward at 1 January	8,244	8,000
Fund balances carried forward at 31 December	8,119	8,244

Balance sheet

Debtors	341	1,133
Cash held centrally for local groups	2,415	1,983
Cash at bank and in hand	5,363	5,128
Net assets	8,119	8,244

Notes:

(a) Income from:

Legacies	505	551
Donations and membership	1,316	1,353
Activities for generating funds (events etc.)	1,900	1,888
Investment income	190	146
Incoming resources from charitable activities – grants	104	65
Total income	4,015	4,003

(b) Expenditure on:

Raising funds	59	62
Charitable activities		
Building your community of support	3,297	3,055
Local group committee costs	42	44
	3,339	3,099
Total expenditure	3,398	3,161

6. Net outgoing resources for the year is stated after charging:

	2025	2024
Fees payable to Group’s auditors:	£’000	£’000
Statutory audit	166	122
Internal audit	98	115
Advisory services (consultancy)	–	37
	264	274
Depreciation & amortisation	843	821
Loss on disposal of fixed assets	–	120
Impairment of intangible fixed assets	–	227
Operating lease rentals	523	820

7. Total resources expended

Group	Grants	Direct costs	Support costs	Total 2025
	£’000	£’000	£’000	£’000
a) Expenditure on Raising funds				
Cost of fundraising activities	–	9,266	2,041	11,307
Trading and merchandising	–	345	–	345
Investment management costs	–	187	–	187
Total costs of raising funds	–	9,798	2,041	11,839

Charitable activities

Getting you new treatments, faster	5,613	3,212	610	9,435
Building your community of support	641	13,265	3,047	16,953
Pushing for excellent health and care	854	6,341	1,698	8,893
Becoming fit for the future	–	4,692	883	5,575
Share of deficit from associates	–	–	–	–
Total expenditure on charitable activities	7,108	27,510	6,238	40,856

Total resources expended	7,108	37,308	8,279	52,695
--------------------------	-------	--------	-------	--------

	IT	Facilities	Human Resources	Finance	Governance	Management	Total 2025
	£’000	£’000	£’000	£’000	£’000	£’000	£’000
b) Support costs apportioned							
Cost of raising funds	758	524	357	232	155	14	2,040
Getting you new treatments, faster	174	154	82	113	76	11	610
Building your community of support	1,333	170	628	515	344	57	3,047
Pushing for excellent health and care	611	374	288	248	166	10	1,697
Becoming fit for the future	329	218	155	104	69	10	885
	3,205	1,440	1,510	1,212	810	102	8,279

Group – prior year	Grants	Direct costs	Support costs	Total 2024
	£'000	£'000	£'000	£'000
a) Expenditure on Raising funds				
Cost of fundraising activities	-	8,100	2,445	10,545
Trading and merchandising	-	337	-	337
Investment management costs	-	201	-	201
Total costs of raising funds	-	8,638	2,445	11,083
Charitable activities				
Getting you new treatments, faster	9,745	6,144	738	16,627
Building your community of support	631	11,927	3,573	16,131
Pushing for excellent health and care	2,244	6,042	2,001	10,287
Becoming fit for the future	-	3,433	971	4,404
Share of deficit from associates	-	1,077	-	1,077
Total expenditure on charitable activities	12,620	28,623	7,283	48,526
Total resources expended	12,620	37,261	9,728	59,609

	IT	Facilities	Human Resources	Finance	Governance	Management	Total 2024
	£'000	£'000	£'000	£'000	£'000	£'000	£'000
b) Support costs apportioned							
Cost of raising funds	1,036	645	330	246	174	14	2,445
Getting you new treatments, faster	242	199	77	120	85	15	738
Building your community of support	1,804	202	574	546	386	61	3,573
Pushing for excellent health and care	823	452	262	264	186	14	2,001
Becoming fit for the future	421	247	134	95	68	6	971
	4,326	1,745	1,377	1,271	899	110	9,728

Allocation of support costs

Directly attributable support costs are allocated as appropriate. Governance costs include the cost of dedicated staff, internal and external audit, the costs of annual local group meetings and the charity’s AGM and direct costs incurred by the board of trustees and its committees and are allocated per distinct budgetary activity. Remaining support costs are allocated as follows:

- IT, Facilities and Human Resources – per employee
- Finance – according to budgetary activity
- Management – per £ of expenditure

The committee cost of local groups, totalling £42,000, are included under the Management heading (2024: £44,000).

8. Amounts committed for grants

Group	Research	Health and care	Physical activity	Financial assistance	Total 2025	Total 2024
	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 1 January	15,854	4,401	80	21	20,356	14,798
Awarded	5,859	854	365	277	7,355	12,871
Unused grants reversed	(246)	-	-	-	(246)	(251)
Payments	(6,938)	(1,306)	(398)	(294)	(8,936)	(7,062)
Balance at 31 December	14,529	3,949	47	4	18,529	20,356
To be disbursed:						
Within one year	8,915	2,434	47	4	11,400	11,544
After more than one year	5,614	1,515	-	-	7,129	8,812
	14,529	3,949	47	4	18,529	20,356

Charity	Research	Health and care	Physical activity	Financial assistance	Total 2025	Total 2024
	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 1 January	14,655	4,401	80	21	19,157	14,798
Awarded	5,388	854	365	277	6,884	9,336
Unused grants reversed	(243)	-	-	-	(243)	(250)
Payments	(5,271)	(1,306)	(398)	(294)	(7,269)	(4,727)
Balance at 31 December	14,529	3,949	47	4	18,529	19,157
To be disbursed:						
Within one year	8,915	2,434	47	4	11,400	10,345
After more than one year	5,614	1,515	-	-	7,129	8,812
	14,529	3,949	47	4	18,529	19,157

All grants were awarded to institutions except financial assistance grants which were for individuals and physical activity grants which were awarded to community organisations.

Health and care grants includes nurse pump priming grants, AHP pump priming grants, fellowships and Excellence Network project grants.

In 2025 all grants were awarded to UK institutions except for the funding for Herantis Pharma Plc which is based in Finland and Critical Path Institute, which is based in the US. In 2024 all grants were awarded to UK institutions except for the funding for Herantis Pharma Plc which is based in Finland, and Neumora Therapeutics and Pretzel Therapeutics which are both based in the US.

There were no currency exchange movements in any grants during 2025 (2024: none).

The basis of allocation of support costs is described in note 7. It is not appropriate to split support costs between grant making and direct service provision as our support functions work across our direct service provision and our grant making activities.

Grants awarded to institutions:	2025	2025	2024	2024
	No of awards	£'000	No of awards	£'000
Research grants				
Imperial College London	2	1,706	2	992
UK Dementia Research Institute	1	1,000	-	-
University College London	3	516	4	927
Herantis Pharma Plc	1	466	1	933
Queen Mary, University of London	2	459	1	248
Cardiff University	2	368	-	-
University of Bristol	1	331	-	-
University of Oxford	1	321	1	288
Queen's University Belfast	1	147	-	-
King's College London	2	141	1	279
Northumbria University	1	108	-	-
Critical Path Institute	1	100	-	-
Oxford Parkinson's Disease Centre	1	90	1	201
University of Cambridge	1	48	3	699
Neumora Therapeutics Inc	-	-	1	2,100
National Institute of Health Research	-	-	1	1,686
Mission Therapeutics Ltd	-	-	1	374
University of Sheffield	-	-	1	255
Pretzel Therapeutics	-	-	1	200
Pathios Therapeutics Limited	-	-	1	199
PolyGeist Limited	-	-	1	196
University of Exeter	-	-	1	133
Project Galaxy (multiple partners)	-	-	1	127
University of Strathclyde	-	-	1	107
Other grants less than £100,000	2	58	-	-
Total research grants	22	5,859	24	9,944

Grants awarded to institutions:	2025	2025	2024	2024
	No of awards	£'000	No of awards	£'000
Health and care grants				
NHS Tayside	1	142	-	-
Whittington Health NHS Trust	1	134	-	-
Lancashire and South Cumbria ICB (Blackburn with Darwen)	1	131	-	-
University Hospitals of Derby and Burton NHS FoundationTrust	1	127	-	-
University Hospitals Plymouth NHS Trust	1	87	-	-
Harrogate and District NHS Foundation Trust	1	75	-	-
Royal London Hospital, Barts Health NHS Trust	1	60	-	-
York and Scarborough Teaching Hospital NHS Foundation Trust	-	-	4	363
North West Anglia NHS Foundation Trust	-	-	2	235
East Sussex Healthcare NHS Trust	-	-	1	142
Livewell Southwest	-	-	1	142
Betsi Cadwaladr University Health Board	-	-	1	140
Whittington Health NHS Trust	-	-	1	135
NHS Highland	-	-	1	121
Kent Community Health Foundation Trust	-	-	1	119
Countess of Chester Hospital NHS Foundation Trust	-	-	1	115
University Hospital Plymouth NHS Trust	-	-	1	115
King's College Hospital	-	-	1	87
University Hospitals Bristol and Weston Foundation Trust	-	-	1	87
University Hospitals Coventry and Warwickshire NHS Trust	-	-	1	87
Leeds Teaching Hospital NHS Trust	-	-	1	87
Homerton University Hospital	-	-	1	82
Bromley Healthcare	-	-	1	60
University of Newcastle Upon Tyne	-	-	1	57
Cardiff and Vale University Health Board	-	-	1	51
Other grants less than £50,000	6	98	7	70
Total health and care grants	13	854	29	2,295

9. Employees, trustees and volunteers

	2025	2024
	£'000	£'000
a) Employee costs:		
Salaries	22,392	20,621
National Insurance contributions	2,760	2,165
Pension contributions	2,426	1,875
	27,578	24,661

Those employees who were members of Parkinson’s UK Aviva pension scheme continue having the offer to opt into a salary sacrifice arrangement. The terms and conditions of employment, for employees who opted in, were revised and sacrificed salary costs are included in pension contributions.

During the year Parkinson’s UK has made termination payments to two employees (2024: one employee) totalling £13,003 (2024: £13,444). Of these payments £nil (2024: £nil) was outstanding at the year end.

Included within this amount were no redundancy costs (2024: £nil) and no payments in lieu of notice (2024: £3,361). Settlement payments of £13,003 were made to two employees during the year (2024: £10,083 to one employee), all of which were made pursuant to legal settlement agreements. No termination payments were made to key management personnel (2024: £nil). There were no ex gratia payments in the current or prior year.

	2025 No.	2024 No.
b) Average number of full-time equivalent staff during year:		
Raising funds	124	115
Getting you new treatments, faster	29	28
Building your community of support	218	201
Pushing for excellent health and care	101	93
Becoming fit for the future	54	47
	526	484

The average number of staff employed during the year was 585 (2024: 534); it consists of 400 (2024: 372) full time employees and 185 (2024: 162) part time employees.

Employee costs are charged to activities either as part of direct cost when staff perform duties directly linked to the activity, or as support costs. Support staff are allocated to charitable activities on the same basis as support costs (as detailed in note 7). When cost of employment is allowed to be charged to a specific restricted fund, this cost will also include pension costs.

	2025 No.	2024 No.
c) The number of employees whose emoluments (including remuneration and benefits in kind and excluding employer pension contributions and employer NI) amounted to more than £60,000 was:		
Band £60,001 to £70,000	20	16
Band £70,001 to £80,000	9	10
Band £80,001 to £90,000	3	2
Band £90,001 to £100,000	2	1
Band £100,001 to £110,000	1	1
Band £110,001 to £120,000	2	1
Band £140,001 to £150,000	–	2

A salary sacrifice arrangement has been in place since 2024, and for those employees who opted in their sacrificed salary has been expensed as a pension contribution. The banding above excludes salary costs which have been sacrificed to pension. Contributions, including salary sacrificed as pension, of £454,938 (2024: £320,213) were made for the provision of defined contribution benefits for 37 (2024: 33) employees earning over £60,000.

The key management personnel of the charity comprise the Executive leadership team listed in the annual report on page 103 and 17 associate directors (2024: 12).

Total remuneration for the key management personnel during the year amounted to £2,357,454 (2024: £2,228,026). The total remuneration for Parkinson’s UK Chief Executive, Caroline Russell, consisted of basic salary before pension salary sacrifice of £149,967 (2024: £147,027) and employer pension contributions of £8,825 (2024: £8,822).

d) Trustees:
No trustees received remuneration for their services in either 2025 or 2024. A trustees’ indemnity policy was purchased at a cost of £15,568 (2024: £14,221).

Trustee expenses were £17,220 (2024: £17,994), of which £522 (2024: £737) was reimbursed for travel and subsistence to 4 trustees (2024: 3 trustees).

e) Volunteers:
The charity has 4,252 (2024: 3,969) active volunteers, the majority of whom have a personal connection to Parkinson’s, either having it themselves or having a relative or close friend with the condition. Our volunteers offer their wealth of skills and experience to support the Parkinson’s community throughout the UK, and drive forward the charity’s key activities of awareness raising, fundraising, research and campaigning.

10. Tangible and intangible fixed assets

Group and charity	Leasehold improvements	Office equipment & fixtures	Computer hardware	Total tangible assets	Intangible assets	Total
	£’000	£’000	£’000	£’000	£’000	£’000
Cost						
At 1 January 2025	768	410	1,113	2,291	2,870	5,161
Additions	–	–	90	90	852	942
Disposal	–	–	–	–	–	–
At 31 December 2025	768	410	1,203	2,381	3,722	6,103
Accumulated depreciation, amortisation and impairment						
At 1 January 2025	41	51	799	891	1,955	2,846
Charge for the year	115	59	162	336	507	843
Disposal	–	–	–	–	–	–
At 31 December 2025	156	110	961	1,227	2,462	3,689
Net book values						
Brought forward at 1 January 2025	727	359	314	1,400	915	2,315
Carried forward at 31 December 2025	612	300	242	1,154	1,260	2,414

No impairment was made in 2025. In 2024 An impairment provision of £227,000 was raised for IT software development costs incurred for current projects in development where it is assessed they may have no future economic benefit.

11. Fixed asset investments

Group	Funds held in managed portfolios	Equity shares	Cash	Other financial instruments	Share of net assets in associates	Investment in trading subsidiaries	Total	Total
	2025	2025	2025	2025	2025	2025	2025	2024
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Valuation at 1 January	36,149	221	-	-	-	-	36,370	39,891
Share of (deficit) in associates	-	-	-	-	-	-	-	(1,077)
Acquisitions at cost	-	-	-	-	-	-	-	2,112
Reinvested investment income	829	-	(829)	-	-	-	-	-
Income received	-	-	873	-	-	-	873	862
Withdrawal	(2,566)	(2)	(44)	-	-	-	(2,612)	(5,739)
Management fee	(187)	-	-	-	-	-	(187)	(201)
Investment impairment provision	-	-	-	-	-	-	-	(1,596)
Net gain / (loss) on revaluation	1,748	(15)	-	-	-	-	1,733	2,118
Valuation at 31 December	35,973	204	-	-	-	-	36,177	36,370

Charity	2025	2025	2025	2025	2025	2025	2025	2024
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Valuation at 1 January	36,149	-	-	-	-	25	36,174	39,122
Reinvested investment income	829	-	(829)	-	-	-	-	-
Income received	-	-	873	-	-	-	873	862
Withdrawal	(2,566)	(4)	(44)	-	-	-	(2,614)	(5,739)
Management fee	(187)	-	-	-	-	-	(187)	(201)
Net gain on revaluation	1,748	-	-	-	-	-	1,748	2,130
Valuation at 31 December	35,973	(4)	-	-	-	25	35,994	36,174

Funds in managed portfolios are held with UK-based institutions. Equity shares are held with US-based biotech companies to develop treatments for Parkinson’s and other related conditions.

	Group	Group	Charity	Charity
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
The historical cost of marketable securities and deposits at 31 December was:	33,111	34,852	27,291	29,031

12. Debtors

	Group	Group	Charity	Charity
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Debtors – amounts falling due within one year				
Legacies	22,746	21,452	22,746	21,452
Amounts due from Parkinson's UK Sales Ltd	-	-	218	55
Convertible loan	720	705	-	-
Tax recoverable on donations and other incoming resources	775	826	775	826
Other debtors	34	39	14	91
Prepayments and accrued income	1,194	2,202	1,128	2,085
	25,469	25,224	24,881	24,509
Debtors – amounts falling due after more than one year				
Amounts due from Parkinson’s Research Ventures Limited	-	-	24,203	20,593
	-	-	24,203	20,593
Total	25,469	25,224	49,084	45,102

The amount of £212,000 (2024: £52,000) due from Parkinson’s UK Sales Limited (excluding Gift Aid contribution) is treated as a concessionary loan and this is not interest bearing.

The amount of £24,203,000 (2024: £20,593,000) due from Parkinson’s Research Ventures Limited is treated as an unsecured intercompany loan and bears interest at 1% above the UK Bank of England base rate as per the loan facility agreement between the two entities.

The convertible loans debtor represents funding provided by Parkinson’s Research Ventures Limited to EndLyz Therapeutics Inc. They are non-basic financial instruments and valued at fair value.

At 31 December 2025, legacies which had been notified but not recognised as incoming resources in the Statement of Financial Activities had an estimated value of £2,214,073 (2024: £3,515,083) which had not been accrued.

13. Creditors – amounts falling due within one year

	Notes	Group	Group	Charity	Charity
		2025	2024	2025	2024
		£'000	£'000	£'000	£'000
Amounts committed to grants	8	11,400	11,544	11,400	10,345
Trade creditors		190	1,416	190	1,351
Tax and social security		-	571	-	571
Accruals		2,055	1,092	1,893	1,016
Deferred income		21	82	-	32
Other creditors		20	289	-	264
		13,686	14,994	13,483	13,579

Group deferred income consists of statutory grant funding and event income received in advance. £21,000 was deferred at 31 December 2025. Income deferred in 2024 of £82,000 was recognised in 2025.

14. Creditors – amounts falling due after more than one year

		Group 2025 £'000	Group 2024 £'000	Charity 2025 £'000	Charity 2024 £'000
	Notes				
Amounts committed to grants	8	7,129	8,812	7,129	8,812
		7,129	8,812	7,129	8,812

15. Financial instruments

At 31 December 2025 the Group held:

		Group 2025 £'000	Group 2024 £'000
Financial assets at amortised cost		37,124	39,114
Financial liabilities at amortised cost		20,793	23,153
Financial assets at fair value through income or expenditure		35,969	36,149

	Income 2025 £'000	Expenses 2025 £'000	Gains 2025 £'000	Income 2024 £'000	Expenses 2024 £'000	Gains/ (losses) 2024 £'000
The Group's income, expense, gains and losses in respect of these financial instruments were:						
Financial assets at amortised cost	362	-	-	489	-	-
Financial liabilities at amortised cost	-	-	-	-	-	-
Financial assets at fair value through income or expenditure	816	-	1,748	825	1,077	2,139

16. Statement of funds

Group	Notes	Balance at 1 January 2025 £'000	Total income £'000	Total Expenditure £'000	Transfers £'000	Net gains on investments £'000	Balance at 31 December 2025 £'000
Unrestricted funds:							
General funds							
Tangible and intangible fixed assets		2,315	-	-	99	-	2,414
Other funds		20,570	35,461	(35,819)	642	1,748	22,602
Total general funds		22,885	35,461	(35,819)	741	1,748	25,016
Designated funds:							
Every Parkinson's Journey		22,855	-	(3,121)	-	-	19,734
Local groups		7,967	3,794	(3,155)	(736)	-	7,870
Total designated funds		30,822	3,794	(6,276)	(736)	-	27,604
Total unrestricted funds		53,707	39,255	(42,095)	5	1,748	52,620
Restricted funds:							
Getting you new treatments, faster							
Research projects	(a)	1,257	7,245	(6,703)	-	-	1,799
Research: The Allan Willett Discovery Fund for Virtual Biotech	(b)	133	-	-	-	-	133
Building your community of support							
Information and support	(c)	5	129	(132)	-	-	2
Parkinson's Connect	(d)	-	-	-	-	-	-
Brakes Connect fund	(e)	190	-	(180)	-	-	10
Geographical	(f)	103	1,357	(1,268)	-	-	192
Local groups	(g)	277	222	(243)	(5)	-	251
Pushing for excellent health and care							
Resources and education	(h)	-	11	(11)	-	-	-
Service improvement	(i)	517	3,201	(2,060)	-	-	1,658
Getting Parkinson's Understood	(j)	-	180	(3)	-	-	177
Total restricted funds		2,482	12,345	(10,600)	(5)	-	4,222
Total funds		56,189	51,600	(52,695)	-	1,748	56,842

Notes	Balance at 1 January 2024 £'000	Total income £'000	Total Expenditure £'000	Transfers £'000	Net gains on investments £'000	Balance at 31 December 2024 £'000
Group – prior year						
Unrestricted funds:						
General funds						
Tangible and intangible fixed assets	1,505	-	-	810	-	2,315
Other funds	30,414	35,312	(40,120)	(7,175)	2,139	20,570
Total general funds	31,919	35,312	(40,120)	(6,365)	2,139	22,885
Designated funds:						
Digital transformation	23,329	-	(7,437)	(15,892)	-	-
Strategic plan investments	-	-	-	22,855	-	22,855
Local groups	7,688	3,708	(2,833)	(596)	-	7,967
Total designated funds	31,017	3,708	(10,270)	6,367	-	30,822
Revaluation reserve	-	-	-	-	-	-
Total unrestricted funds	62,936	39,020	(50,390)	2	2,139	53,707

Restricted funds

Getting you new treatments, faster

Research projects	(a)	1,131	4,547	(4,421)	-	-	1,257
Research: The Allan Willett Discovery Fund for Virtual Biotech	(b)	7	914	(788)	-	-	133

Building your community of support

Information and support	(c)	94	110	(199)	-	-	5
Parkinson's Connect	(d)	2	0	(2)	-	-	0
Brakes Connect fund	(e)	243	10	(63)	-	-	190
Geographical	(f)	6	1,777	(1,680)	-	-	103
Local groups	(g)	312	295	(328)	(2)	-	277

Pushing for excellent health and care

Resources and education	(h)	-	107	(107)	-	-	-
Service improvement	(i)	362	1,786	(1,631)	-	-	517
Getting Parkinson's Understood	(j)	-	-	-	-	-	-

Total restricted funds		2,157	9,546	(9,219)	(2)	-	2,482
Total funds		65,093	48,566	(59,609)	-	2,139	56,189

General funds

In 2025 the Group and Charity revaluation reserve is included in the balance sheet unrestricted funds.

Restricted funds

- (a) Research projects funds are used to meet the direct costs of the charity's medical research projects.
- (b) The Allan Willett Discovery Fund is to meet the costs of the Virtual Biotech programme.
- (c) Information and support funds are used to provide country-wide support for people affected by Parkinson's including the helpline.
- (d) The Parkinson's Connect fund is to support the charity's personalised support service for people with Parkinson's.
- (e) The Frank and Evelyn Brake Connect Fund was set up in 2021 to support the rollout of Parkinson's Connect and the transformation of the information and support services.
- (f) Geographically restricted funds are used to fund local services for people affected by Parkinson's in specific countries or regions in the UK.
- (g) Local groups funds are held by volunteer led local groups and are primarily used to provide friendship and support at a local level.
- (h) Resources and education funds are used to meet the cost of creating information resources for people affected by Parkinson's and to provide resources and ongoing professional development for health care professionals.
- (i) Service improvement funds are used to meet the costs of the charity's nurse and allied healthcare professional development and clinical fellowship grants.
- (j) Getting Parkinson's Understood funds are used to support the cost of raising public awareness of Parkinson's

Transfers

Following the CC19 compliant review of the Charity's reserves policy in 2024 and a new risk based approach was approved, which now considers the risk associated with a number of key areas. Within the policy, local groups activities are held as designated funds set aside by our Board of Trustees, so they are excluded from our reserves calculation, alongside our fixed asset reserve.

The Board of Trustees approved at its meeting in December 2025 the continued designation of Strategic Plan Investments within the Every Parkinson's Journey fund. Ongoing expenditure from this fund in 2025 saw spends of £3.1m in 2025 (2024: £nil). This brings the total designated fund to £19.7m (2024: £22.9m), to continue support for our strategy spend for 2026-27.

The transfer of £5,000 in 2025 (2024: £2,000) from local group restricted to unrestricted funds reflects income received by some local groups which was then classified as unrestricted income and was used to support purchases within UK programmes.

Analysis of net assets between funds:	Unrestricted funds	Restricted funds	Total funds	Unrestricted funds	Restricted funds	Total funds
	2025 £'000	2025 £'000	2025 £'000	2024	2024	2024
Group	£'000	£'000	£'000	£'000	£'000	£'000
Intangible assets	1,260	-	1,260	915	-	915
Tangible fixed assets	1,154	-	1,154	1,400	-	1,400
Investments	36,177	-	36,177	36,370	-	36,370
Current assets	31,230	7,836	39,066	33,379	7,931	41,310
Long-term debtors	-	-	-	-	-	-
Liabilities	(17,201)	(3,614)	(20,815)	(18,357)	(5,449)	(23,806)
Net assets	52,620	4,222	56,842	53,707	2,482	56,189

	Unrestricted funds	Restricted funds	Total funds	Unrestricted funds	Restricted funds	Total funds
	2025 £'000	2025 £'000	2025 £'000	2024	2024	2024
Charity	£'000	£'000	£'000	£'000	£'000	£'000
Intangible assets	1,260	-	1,260	915	-	915
Tangible fixed assets	1,154	-	1,154	1,400	-	1,400
Investments	35,994	-	35,994	36,174	-	36,174
Current assets	30,212	7,836	38,048	32,425	7,931	40,356
Long-term debtors	24,203	-	24,203	20,593	-	20,593
Liabilities	(16,998)	(3,614)	(20,612)	(16,942)	(5,449)	(22,391)
Net assets	75,825	4,222	80,047	74,565	2,482	77,047

17. Accounting estimates and judgements

In preparing the financial statements, the trustees are required to make estimates, judgements and assumptions. The most important areas where the judgements affect the financial statements and could impact the results of reported operations are listed below.

Grants commitments

Parkinson’s UK makes grant commitments and recognises the expenditure in the year when the commitment is made. Most of the commitments become payable within two to three years. Judgement is exercised when subsequent payments are released upon receipt of a report showing satisfactory progress being made against agreed outcome. Outstanding amounts are not discounted on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Cost allocation

Costs not attributable to a single activity are allocated or apportioned to activities on a basis consistent with identified drivers for that cost category. As stated in note 7(b), cost drivers may be headcount, cost centre or floor space and a judgement is made in applying these cost drivers to the cost categories.

Legacy income

A prudent estimate of legacy income due is now achieved using probate information, together with an estimate of 5% for legacy administration fees where appropriate. An annual review of legacy valuations and administration fees ensures any estimates are adjusted in line with current data. Whilst inherent uncertainty remains when considering estate valuations, due to the nature of probate, the analysis provides assurance that our legacy estimates are as accurate as they can be within the given accounting period.

Complex financial instruments

The charity group had five complex financial instruments at the balance sheet date in 2025 (2024: four complex financial instruments). The complex financial instruments are linked to the partnerships with EndLyz Therapeutics Inc and Acurex Biosciences Corporation and are convertible loans issued in 2023 and 2024. The instruments were measured at fair value at the balance sheet date in accordance with the relevant accounting standards. The fair value of these instruments is determined using a discounted cash flow methodology based on the expected redemption proceeds of the loan notes. The valuation incorporates the contractual principal balances, accrued interest to the expected redemption date and a discount rate reflecting both the time value of money and the credit risk associated with the issuer.

The discount rate is derived from a risk-free rate based on the Secured Overnight Financing Rate (“SOFR”) together with a credit spread determined by reference to comparable biotechnology and pharmaceutical debt instruments. As the issuer is a private early-stage biotechnology company with no quoted debt instruments, significant judgement is applied in selecting appropriate market comparators and determining the resulting credit spread. At 31 December 2025, the yield used to discount expected future cash flows was approximately 8.4%.

18. Related and connected party transactions

In accordance with FRS102 section 33, the charity discloses the following related party transactions:

Research grants as summarised below were awarded to projects involving a member of the charity’s Grant Assessment College of Experts (COE) in the capacity as research professional or other related party. The individuals below did not participate in the decisions to award these grants to their respective organisations.

Related party	Organisation	Relationship	Grants awarded during 2025	Outstanding balance at 31 December 2025
			£’000	£’000
Grant lead applicants				
No lead applicants to disclose				
Grant co-applicants				
Dr William Young	Cardiff University	Member of COE	231	231

Group – Prior Year

Related party	Organisation	Relationship	Grants awarded during 2024	Outstanding balance at 31 December 2024
			£’000	£’000
Grant lead applicants				
Dr William Young	University of Exeter	Member of COE	133	133
Dr Caroline Williams–Gray	University of Cambridge	Member of COE	199	199
Professor Anja Lowit	University of Strathclyde	Member of COE	107	107
Dr Marta Carmacho	University of Cambridge	Member of COE	300	300
Grant co-applicants				
Professor Andrey Abramov	Institute of Neurology, UCL	Member of COE	284	284
Dr Angeliki Zarkali	University College London	Member of COE	334	334
Dr Marta Camacho	University of Cambridge	Member of COE	199	199
Dr Jeff Davies	University of Cambridge	Member of COE	199	199
Dr Caroline Williams–Gray	University of Cambridge	Member of COE	300	300

Donations from trustees

During 2025 the charity received donations totalling £1,517 (2024: £1,665) from Trustees of the charity.

Transactions within the group	2025 Net income to charity	2025 Balance owed to charity at 31 December	2024 Net income to charity	2024 Balance owed to charity at 31 December
	£’000	£’000	£’000	£’000
Transaction between Parkinson’s UK and Parkinson’s UK Sales Limited	48	218	110	55
Transaction between Parkinson’s UK and Parkinson’s Research Ventures Limited	1,765	24,200	1,371	20,593

All transactions above resulted from transfers between members of the group relating to the operational activities of the trading subsidiaries including administration fees of £52,000 (Parkinson’s UK Sales Limited) and £559,000 (Parkinson’s Research Ventures Limited) charged by the charity, interest due to the charity on the secured loan to Parkinson’s Research Ventures Limited of £1,206,000 and transfer of profits of £6,000 from Parkinson’s UK Sales Limited to the charity under the gift aid scheme, offset by purchases of merchandise by the charity.

In 2024 the amounts were administration fees of £112,000 (Parkinson’s UK Sales Limited) and £307,000 (Parkinson’s Research Ventures Limited), interest of £1,064,000 (Parkinson’s Research Ventures Limited) and transfer of profits of £3,000 (Parkinson’s UK Sales Limited).

19. Operating lease commitments

As at 31 December 2025 the charity had annual operating lease commitments as set out below:

	2025	2025	2024	2024
	Land and	Other	Land and	Other
	buildings		buildings	
	£'000	£'000	£'000	£'000
Operating leases payments due:				
within one year	254	7	236	5
within two to five years	1,825	26	2,301	14
after five years	-	-	-	-
	2,079	33	2,537	19

The current 10 year lease at 50 Broadway contains a five year break clause and lease commitments to July 2029 are included in the table above.

20. Grants received

In accordance with agreements entered into with grantors the charity acknowledges the receipt of the following grants included within the net grant income of £332,000 (2024: £332,000)) in the statement of financial activities.

Grantor	Activity	2025	2024
		£'000	£'000
The National Lottery Community Fund Wales	Parkinson's Community Cymru	93	162
The National Lottery Community Fund	Hastings and Bexhill Support Group – Group activities	20	-
The National Lottery Community Fund	Croydon Branch – Exercise classes	20	-
The National Lottery Community Fund	Barnsley Branch – Respite Care	15	10
Sport England	Tamworth Support Group – Exercise classes	8	-
Sport England	Chorley and South Ribble Branch – Group classes	6	5
Sport England	Redbridge and Epping Forest Branch – Non-contact boxing	6	-
Northern Ireland Department of Health Mental Health Fund/the Community Foundation	Parkinson's: Who Cares?	5	22
Groundwork: Walking and Cycling Grants London	Kensington and Chelsea Support Group – Start up total body walking	5	-
Universtiy Hospitals Bristol	Research Involvement	2	-
Spelthorne Borough Council	Spelthorne Parkies Support Group – Group activities	2	-
Mid Ulster District Council	Spires Magherafelt Branch – Group activities	2	-
Pembrokeshire County Council	Pembrokeshire Branch – Holiday transport	1	5
Exmouth Town Council	East Devon Support Group – Exercise classes	1	1
Winkfield Parish Council	Bracknell and District Branch – Group activities	1	1
Binfield Parish Council	Bracknell and District Branch – Group activities	1	-
Bracknell Town Council	Bracknell and District Branch – Group activities	1	-
Lymington Town Council	The New Forest Branch – Group activities	1	-
Warfield Parish Council	Bracknell and District Branch – Group activities	1	-
Medical Research Council – UKRI emergency grant 2021-22	Early Career Researchers Support	-	32
The National Lottery Community Fund Scotland	Parkinson's Active	-	31
Arts Council of Wales	SParky Samba	-	12
The National Lottery Community Fund	South London Younger Parkinson's Network – Popping for Parkinson's classes	-	10

The National Lottery Community Fund	North Down Support Group – Therapy Sessions	-	10
Northern Ireland Department of Health Mental Health Fund/the Community Foundation	Parkinson's Minds Matter	-	8
The National Lottery Community Fund	Ashbourne and District Branch – Exercise classes	-	8
Sport England	Kettering and District Branch – Exercise classes	-	3
Calderdale Metropolitan Borough Council	Halifax Branch – Carers Grant	-	2
West Suffolk Council	Bury St Edmunds Branch – Parkinsongsters	-	1
Royston Town Council	Royston Activity Group – Group activities	-	1
New Forest District Council	The New Forest Branch – Group activities	-	1
North Yorkshire Council	Ryedale Support Group – Group activities	-	1
Royal Wootton Bassett Town Council	Swindon Parkinson's Activity Group – Cafe groups	-	1
Other grants under £1,000		12	5
Total grants		203	332

21. Contingent liabilities

At the year end the Group had six outstanding performance-related research funding commitments that were not fully included in the balance sheet as the related payments are possible but subject to satisfactory review. The costs are recognised in the statement of financial activities when performance criteria are met. The grants are listed below:

Name of institution and grant title	Nature of contingency	Timescale for remaining commitment years	Total award	Amount not recognised at 31 December 2025
			£'000	£'000
Imperial College London – Parkinson's UK-MS Society Tissue Bank	Performance-related grant	2026-2029	1,524	956
UK Dementia Research Institute – Parkinson's Research Centre	Performance-related funding	2026-2029	5,000	4,000
Imperial College London – Landmark Study	Performance-related grant	2025-2029	4,350	2,200
Syntara Ltd – Multicentre clinical trial	Performance-related funding	2026	2,900	1,150
Mission Therapeutics Ltd – Clinical trial	Performance-related funding	2026-2027	1,252	876
Herantis Pharma Plc – Clinical trial	Performance-related funding	2026	1,555	155

22. Contingent assets

All of Parkinson's Virtual Biotech project funding agreements include a provision for a financial return in the case the sponsor receives revenues from commercialisation. At the end of 2025 there were however no cases in which there was expectation of a specific return over the coming year (2024: none). The income is recognised in the statement of financial activities when the income recognition criteria is met.

23. Post balance sheet events

There have been no post-balance sheet events that require adjustment to or disclosure in these financial statements.

Reference and administrative details

Charity details

Parkinson’s UK (registered as the Parkinson’s Disease Society of the United Kingdom)
Registered office 50 Broadway, London SW1H 0DB
parkinsons.org.uk
Company registered in England and Wales number 00948776
England and Wales charity number 258197
Scottish charity number SC037554
There are biographies of all our Trustees on our website.

Composition of board of trustees (as at 31 December 2025)			
Name	Type	Nation	Percentage of eligible scheduled Board meetings attended
Gary Shaughnessy CBE (Chair of the Board)	A	N/A	100
Matthew Durdy (Vice Chair of the Board, Chair of the board of Parkinson’s Research Ventures Limited)	A	N/A	100
Jane Burston OBE	E	England	80
Brian Carson	E	Scotland	100
Elaine Evans	E	Wales	100
Ian Garland	A	N/A	100
Katrina Green (Chair of the Audit and Risk Committee)	A	N/A	100
Pamela Harding (Chair of the People Committee)	A	N/A	100
Dr Sangeeta Kulkarni	A	N/A	100
Peter Miller	E	England	100
Graham Pierpoint	E	Northern Ireland	100
Kate Platts	E	England	100
Janet Shipton	E	England	100

Key – A=Appointed, E=Elected
Notes:
Kyle Alexander, Samantha Aylieff, Sally Bromley, Andrew Cavey and Annie McCallum stood down from the board in October 2025 at the end of their respective terms. Matthew Durdy stood down from the board in March 2026 at the end of his term. Professor Sonia Gandhi joined the board from March 2026. Ian Garland was appointed Chair of Parkinson’s Research Ventures Limited from February 2026. Peter Miller was appointed Deputy Chair of Parkinson’s UK from February 2026. Kate Platts was appointed Chair of the new Finance and Performance Committee from February 2026.

Executive Leadership team

There are biographies for all our Executive Leadership team members on our website.

- Caroline Russell, Chief Executive
- Adrian Blair, Chief People Officer
- Ben Clarkson, Chief Finance and Operating Officer
- David Dexter, Director of Research
- Paul Jackson–Clark, Director of Fundraising and Experience
- David Newbold, Director of Community
- Juliet Tizzard, Director of External Relations (until May 2026)

Professional advisers

Auditors (external)

BDO LLP
55 Baker Street
Marylebone
London
W1U 7EU

Auditors (internal)

Grant Thornton LLP
30 Finsbury Square
London
EC2A 1AG

Bankers

Barclays
1 Churchill Place
London
E14 5HP

Royal Bank of Scotland
97 New Bond Street
London
W1S 1EU

Solicitors

Withers LLP
20 Old Bailey
London
EC4M 7AN

Investment managers

JP Morgan Bank S.E.
60 Victoria Embankment
London
EC4Y 0JP

Troy Asset Management Limited
33 Davies Street
London
W1K 4BP

Thank you

Our Patron

HRH The Duchess of Gloucester GCVO

Our President

Jane Asher

Our members

Membership of Parkinson’s UK is free. It gives our members community connections, information and support, and opportunities to be heard and to help make a difference to our work. Thank you to everyone who joined or continued to support us in this way and made a difference as a member in 2025.

Our colleagues and volunteers

Our colleagues and volunteers are highly skilled and talented people who tirelessly use their expertise to make life better every day for everyone in the Parkinson’s community. Their tremendous effort across the year means we have made huge progress on all fronts.

Charitable trusts, foundations and statutory organisations

Arts Council of Wales

Edith Murphy Foundation

Fund Léon and Miriam Velge, managed by the King Baudouin Foundation

Garfield Weston Foundation

Gatsby Charitable Foundation

J Macdonald Menzies Charitable Trust

Miss Isabel Harvey Charitable Trust

Mrs Mary Patricia Moss
Discretionary Settlement

Parkinson’s Foundation

Randal Charitable Foundation

ShareGift

The Arthur Ronald Dyer Charitable Trust

The EH Trust and The PH Trust

The Freddie Green and Family Charitable
Foundation

The Geoff Payne Family and Friends Charity

The Gerald Micklem Charitable Trust

The Grace Trust

The Heather Beckwith Charitable Settlement

The Michael Cornish Charitable Trust

The Michael J. Fox Foundation for Parkinson’s
Research


The National Lottery Community Fund

Cronfa Gymunedol y Loteri Genedlaethol

The P F Charitable Trust

The Peacock Charitable Trust

The TJH Foundation



Companies and other organisations

Abacus Cards

Asian Achievers Awards

Association for Public Service Excellence

Big Give

Hamilton Global Specialty

Hat and Home

National Garden Scheme

Next PLC

Paydens Group

Project Giving Back

Smart Outdoor

Swan Mill Group

Theraposture Ltd

ThinCats

Trainline

Yeomans

Those who remembered us in their will

We are enormously grateful to all those who have included a gift to Parkinson’s UK in their will. In 2025, we were notified of 642 new legacy gifts. Gifts in wills continue to be our largest source of income, making up more than half of all our voluntary income. These thoughtful gifts fund groundbreaking research and life-changing support services, and enable us to help thousands of people living with Parkinson’s and those who love and care for them.

Those who gave in memory of a loved one

This is a wonderful way to remember and celebrate a loved one’s life. These donations will continue to make a real difference to people with Parkinson’s for many years to come. We’re so thankful for everyone who chose to honour a loved one in this way.

Fundraisers

Almac Group Ltd

Daniel Charles Construction Ltd

Dion Kitson Studio

Eamon McConville

G L P UK Management Ltd

Gary Shaughnessy CBE

Gillian Key

Hayward Wright Accountancy and Advisory

Helen Spencer

Hemley Hillbillies and Lyn’s Plants

John Weston

Manjinder Mahil

Mark Jones

Michelle Dunkley

Nichola Macer

Pete Lindsay and Dean Stephenson

Phillip Jones

Rebecca and Fergus Walker

Southampton Property Association

Stockton-on-Tees Borough Council

Struan Tea

Vickie’s Parkinson’s Shop CIC

Regular givers

Regular donations mean we can plan ahead and invest in long-term research projects and health and care services supporting people living with Parkinson’s. We’re incredibly grateful to the generous people who choose to give regularly. The impact they make is astonishing.

Philanthropists

- Alan Jackson
- Andrew Cohen Charitable Trust
- Andrew, Peter and Ruth Bolton
- Blobel Family 2003 Trust
- Brenda Edney
- Dudley and Diane Eustace
- Felicity Percy
- Fiona Wilson MBE
- Flagship Gala Event Committee
- Frank Brake Charitable Trust
- Graham and Jenny Murphy
- John and Wendy Havens
- Miss Stephanie Pattenden
- Mrs Georgina Erskine in memory of David Erskine
- Ms Anupama Dikshit
- Pappudu Sriram and Rajesh Venkataramani
- Rachel Mason and Jack Thorne
- Rich and Anna Youle
- Scott and Caroline Beaumont
- Tessa Martin-Bird
- The Sloane Family

The William Brake Foundation

William Newsom

High-profile supporters

- Angela Rippon CBE
- Anne Twist
- Aidy and Emma Boothroyd
- Alexandra Burke
- Catherine Tyldesley
- Charlotte Edwards
- Dave Clark
- Dipna Anand
- Dougray Scott
- Dr Ed Patrick
- Gavin Hastings OBE
- Gbemi Oladipo
- Jane Asher
- Jane Hill
- Mark Mardell
- Nick Elphick
- Paul Mayhew Archer MBE
- Paul Longley
- Paul Sinha
- Rob Deering
- Rory Cellan-Jones OBE
- Samantha Spiro
- Simone Ashley
- Tom Price
- Tom Read Wilson



Parkinson’s UK supporters,
London Marathon, 2026

We're Parkinson's UK, the charity that's here to support every Parkinson's journey.

We will find a cure, but it's not all we're working for. We're making a difference now. Funding research into groundbreaking new treatments. Campaigning for better health and care services. And building strong, supportive communities.

Free confidential helpline providing information and advice to anyone affected by Parkinson's

Call **0808 800 0303**, Monday to Friday 9am to 6pm, Saturday 10am to 1pm (interpreting available)

NGT Relay **18001 0808 800 0303** (for textphone users only)

Or email hello@parkinsons.org.uk

To become a Parkinson's UK member or to donate, volunteer, raise money for us or campaign with us, call our Supporter Care team on 0800 138 6593

Or visit membership@parkinsons.org.uk

Or visit parkinsons.org.uk

